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ABSTRACT 
 
Hereditary Hemochromatosis (HH) is an inherited recessive autosomal disorder  
 
characterized by accumulation of excess iron. When iron binding proteins become 
 
saturated, concentrations of free, or non-transferrin-bound iron (NTBI) rise, a condition 
 
thought to be responsible for the adverse effects associated with HH. To investigate that 
 
disturbing iron homeostasis plays a role in free radical injury in HH, protein carbonyls were 
 
found to be 1-7 times higher in patients with HH than in controls, with the greatest increases 
 
being observed in untreated HH patients with high ferritin and >90% transferrin saturation  
 
with iron. An Unpaired t test revealed a P value of 0.0278 (P< 0.05), which is considered to  
 
be statistically significant. Our data showed a significant positive correlation (linear  
 
relationship) between the level of carbonyl content and ferritin concentration in plasma  
 
samples from patients with HH. In vitro oxidation of transferrin and ferritin standards with  
 
hydrogen peroxide and excess iron, followed by immobilized trypsin digestion (Poroszyme),  
 
high-resolution LC-MS/MS analysis (Q-TOF Ultima, Waters) and MS/MS data processing  
 
(PEAKS, Bioinformatics Solution), identified several tryptic peptides containing oxidized Met,  
 
Trp and His residues. Mapping of the oxidized ferritin residues showed them to be located on  
 
the inner face of each sub-unit, the face directed toward the ferritin core where iron is  
 
normally stored. Using the same methodology, oxidized residues were subsequently  
 
detected in ferritin and transferrin isolated from plasma samples of patients severely affected  
 
with HH. Comparing of MS/MS spectra of in vitro oxidized samples that have most fragment  
 
ion peaks in common with oxidized peptide MS/MS spectra from samples of patients with HH  
 
revealed a significant correlation between the two. These data show that elevated NTBI  
 
may be involved in oxidative modification of the iron binding proteins, ferritin and transferrin, 
 
and that such modifications may play a significant role in the pathophysiology of HH. 
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1.0 Introduction 
 
Protein oxidation is the covalent modification of a protein induced either directly by  
 
reactive oxygen species (ROS) or indirectly by reaction with secondary by-products of 
 
oxidative stress (Shacter, 2000). Mitochondria are the major source of cellular ROS in non- 
  
phagocytic cells. Toxic oxygen metabolites are physiologically generated at a low level in 
 
cells and tissues during oxidative phosphorylation (Stadtman, E. et al. 1998). The resulting 
 
low levels of ROS play an integral part in modulation of several physiological functions of the 
 
cell, including gene expression, signal transduction, and defense against invading pathogens 
 
(Stadman, E. et al. 1998). ROS have the ability to damage all biomolecules including  
 
proteins, lipids, DNA and carbohydrates. ROS such as superoxide anion (O2¯·), hydrogen 
 
peroxide (H2O2) and the hydroxyl radical (·OH) are formed in the course of normal 
 
metabolism through leakage of electrons from the electron transport chain and by activities of 
 
oxidoreductase enzymes such as NADPH oxidase, myeloperoxidase, xanthine oxidase,  
 
glucose oxidase, the cytochrome P450 and cyclooxygenases (Shacter, 2000). Under normal 
 
conditions, up to 1% of the mitochondrial electron flow leads primarily to the formation of  
 
O2¯·. Interference with electron transport can dramatically increase O2¯· production, which is 
 
rapidly converted within the cell to H2O2 and O2 by the superoxide dismutases (SODs). H2O2 
 
can react with reduced transition metals [Fe(II), Cu (I)] via the Fenton reaction to produce the 
 
highly reactive hydroxyl radical. Alternatively, H2O2 may be converted into water by the  
 
enzyme catalase and glutathione peroxidase (Stadtman, E. et al. 1998). The modification of  
 
proteins is initiated mainly by the reactions with ·OH; however, the course of the oxidation  
 
process is determined by the availability of O2 and O2¯·. 
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Collectively, ROS can lead to oxidation of amino acid residue side chains, formation of 
 
protein-protein cross-linkages and oxidation of the protein backbone resulting in protein 
 
fragmentation (Dean, R. et al., 1997). In addition, some other agents are involved in 
 
initiating protein oxidation such as HOCl (Shacter, 2000; Heinecke J. et al. 1993; 
 
Schraufstatter, I. et al. 1990; Handelman, G. et al., 1998; Yang, C. et al. 1997; Yan, L.et al. 
 
1996), xenobiotics such as paraquat (Korbashi, P. et al., 1986; Hartley, D. et al. 1997), 
 
acetaminophen (Tirmenstein, M. et al., 1990), cigarette smoke (Eiserich, J. et al. 1995), γ- 
 
irradiation in the presence of O2 (Berlett, B. et al. 1997; Steinbrecher, U. et al. 1987; Yan, L. 
 
et al. 1997), activated neutrophils (Davies, K. et al. 1987), UV light (Davies, K. et al. 1987; 
 
Fu,S. et al. 1997; Oliver, C. et al. 1987), ozone (Balasubramanian, D. et al. 1990), and by- 
 
products of lipids and free amino acid oxidation (Shen, H. et al. 1996; Hu, M. et al. 1992; 
 
Cross, C. et al. 1992). Due to the oxidative modification of many amino acid side chains,  
 
there are numerous types of protein modifications. The two amino acids that are especially  
 
prone to oxidative attack are Cys (Shacter, 2000; Radi, R.et al. 1991; Lii, C-K. et al. 1994)  
 
and Met (Shacter, 2000, Vogt, W. 1995), both of which contain susceptible sulfur containing  
 
amino acids (thiols). Indeed, most if not all ROS can induce modifications of Cys and Met. In  
 
the case of Cys, oxidation leads to the formation of disulfide bonds, mixed disulfides and thiyl  
 
radicals (Hu, M. et al. 1994; Kalyanaraman, B. et al. 1995). With Met residues, the major  
 
product under biological conditions is Met sulfoxide (Volt, W. 1995). Other amino acid  
 
moieties, especially Lys, Arg, Pro, and Thr (Shacter, 2000; Amici, A. et al. 1989) participate in  
 
the formation of carbonyl groups (aldehydes and ketones) on the side chains. The interaction 
 
of HOCl with Tyr, Trp, Lys and Met residues leads to formation of chlorotyrosine,  
 
chloramines, aldehydes and Met sulfoxides (Hazell, L. 1994; Hazen, S. et al 1997). Additional  
 
aspects of the oxidative modification of the protein will be reviewed in a subsequent section. 
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Protein oxidative modifications are summarized in Table 1. Because of the potential of ROS 
 
to induce significant biological damage, cells and tissues have an abundance of antioxidant  
 
systems to scavenge or eliminate them. These include antioxidant enzymes such as  
 
catalase, superoxide dismutases and glutathione peroxidase as well as low molecular weight  
 
scavengers such as vitamins C and E as well as reduced glutathione (GSH). Under normal 
 
conditions there is a well managed balance between formation and neutralization of ROS, so 
 
there is little or no modification of biomolecules. However, “ oxidative stress “ occurs when  
 
the balance of formation of oxidants exceeds the ability of antioxidant systems to remove or 
 
scavenge ROS (Shacter, 2000). 
                               
Table 1: Oxidative Modifications of Proteins 
 
Modification                               Amino acid involved                      Oxidizing source 
       Disulfides,glutathionation             Cys                                                      All, ONOO¯ 
       Methionine sulfoxide                    Met                                                      All, ONOO¯ 
       Carbonyls (aldehydes, ketones)  All esp (Lys, Arg, Pro, Thr                   All 
       Oxo-histidine                                His                                                       γ-Ray, MCO 
       Dityrosine                                     Tyr                                                       γ-Ray, MCO       
       Chlorotyrosine                              Tyr                                                       HOCl 
       Nitrotyrosine                                 Tyr                                                       ONOO¯ 
       Tryptophanyl modifications,         Trp                                                        γ- Ray  
       Hydro (pero) xy derivatives          Val,Leu,Tyr,Trp                                    γ-Ray 
       Chloramines,deamination            Lys                                                        HOCl 
       Lipid peroxidation adducts           Lys,His,Cys                                          γ-Ray, MCO 
       (MDA, acrolein, NHE) 
       Amino acid oxidation adducts      Lys, His,Cys                                         HOCl 
       Glycosidation adducts                  Lys                                                       Glucose 
       Cross-links,aggregates,               Several                                                 All 
 
MCO; metal-catalyzed oxidation; All = γ-Ray, MCO, HOCl, ozone, O2, MDA;  
 
Malondialdehyde.    
 
1.2 Is oxidative modification reversible? 
 
Reversible modifications, usually at Cys residues, may have a dual role of protection from 
 
irreversible damage and modulation of protein function (redox regulation). Irreversible 
 
modifications induced by ROS, such as di Tyr formation, protein-protein cross-linking, Lys 
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and Arg carbonylation are generally associated with permanent loss of function and may 
 
lead to either degradation of the damaged proteins (Berlett & Stadtman, 1997; Davies and 
 
Dean et al. 1997; Grune et al. 2003) or their progression into cytoplasmic inclusions, as 
 
observed in age-related neurodegenerative disorders (Giasson et al. 2000, 2002; Butterfield 
 
and Kanski, 2001). 
 
1.3 Advantages of protein oxidation as a biomarker for oxidative stress 
 
These include: 
 
1. Relatively stable. 
 
2. Types of modification reveal nature of the oxidizing agents (chlorotyrosine from 
 
HOCl, nitrotyrosine from ·NO and glutamic and aminoadipic semialdehydes from 
  
      MCO).  
 
3. Due to the specificity of protein functions, they have unique physiological 
 
      consequences. 
 
4. Availability of sensitive assays, which can detect as low as 1 pmol of oxidized  
 
      product. 
 
1.4 Radical-mediated protein oxidation 
 
Protein oxidative modification is most likely to be mediated by free radical generation. A free 
 
radical is any molecular species capable of independent existence that contains one or more  
 
unpaired electrons. An unpaired electron is one that occupies an atomic or molecular orbital  
 
by itself. The presence of one or more unpaired electrons causes the species to be attracted  
 
slightly to a magnetic field (paramagnetic), and sometimes makes the species highly reactive  
 
(Cutteridge et al. 1989).The primary radical in most oxygenated biological systems is the  
 
superoxide ion (O¯2), which is in equilibrium with its protonated form, the hydroperoxyl radical  
 
(HO2˙). The major sources of these radicals are modest leakages from the electron transport 
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chains of mitochondria, chloroplasts, and endoplasmic reticulum. Although O¯2 is relatively 
 
unreactive in comparison with other radicals, biological systems can convert it into other  
 
more reactive species such as peroxyl (ROO·), alkoxyl (RO·) and hydroxyl radical (OH·).  
 
1.4.1 Transition Metals 
 
In their reduced forms, these metals catalyze the production of radicals from H2O2 via the  
 
Fenton reaction. From a radical point of view, the transition metals of interest are those that  
 
have variable valence which allows them to undergo changes in oxidation state involving one  
 
electron. This holds true for Fe, Cu and Mn but not Zn which has only one valence which,  
 
unlike Fe, Cu, and Mn, prevents it from promoting radical reactions. 
 
1.4.2 Fenton Reaction 
 
A mixture of H2O2 and Fe (II) salt reacts with many organic molecules, as was first observed 
 
by Fenton in 1894. The reactivity is most likely due to formation of the hydroxyl radical (·OH): 
 
           Fe+²    + H2O2             Fe+3        + ·OH + OH¯ 
 
Traces of Fe (III) can react further with H2O2: 
 
           Fe +3     + H2O2             Fe +²    +  O2¯ + 2H 
 
Haber-Weiss reaction is a possible fate either iron- or copper-catalysed: 
 
           H2O2  + O¯2               O2  +  OH¯ + .OH 
 
Further reactions are also possible: 
 
            O2¯   + Fe +3               Fe +²  +  O2 
 
           ·OH    + Fe +²             Fe +3   +   HO¯ 
 
1.5 Non-radical mediated protein oxidation 
 
So far, two categories of non-radical intermediates in protein oxidation have been identified. 
 
Reactive moieties, notably DOPA, formed from tyrosine, can reduce transition-metal ions,  
 
thus enhancing reactions with hydroperoxides which are also able to induce radical 
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formation in reactions with O2 (Davies, M. et al. 1997; Simpson J. et al. 1992; Gieseg, S. 
 
et al. 1993). The other category is hydroperoxides formed particularly on unsaturated 
 
aliphatic hydrocarbon side chains but probably also on main-chain α-chain carbons 
 
(Dean R. et al. 1996; 1995; Simpson, J. et al. 1992). These can be decomposed by  
 
transition-metal ions to give further radicals. The hydroperoxides can also be reductively  
 
detoxified to hydroxides probably without radical formation (Fu, S. et al. 1995). 
 
1.6 An Overview for Oxidative Modifications of Different Amino Acids 
 
1.6.1 Oxidative Modification of Protein Thiols 
 
Thiol groups are easily oxidized by many ROS. Their modifications may have different  
 
physiological effects, depending on their reversible or irreversible nature. Mild oxidation of 
 
cysteines generates sulfenic acid, inter- or intra-molecular disulfides, protein mixed disulfides 
 
with low molecular weight thiols (e.g., GSH), and S-nitrosothiols. These reversible  
 
modifications can be part of regulatory processes of protein functions, in which cysteines 
 
can cycle between the oxidized and reduced state. Basically, sulfenic acid is unstable, being 
 
an intermediate in sulfinic and/or sulfonic acid generation. However, Cys residues can be 
 
irreversibly oxidized by strong oxidative agents to sulfinic and sulfonic acids, which cause  
 
loss of protein function and cannot be reversed by metabolic processes (Woo et al. 2003). 
 
1.6.1.1 Possible Methods for Analysis of Oxidized Products of Protein Thiols 
 
Formation of inter-molecular disulfides following oxidative insult generates macroscopic 
 
variation of protein molecular mass. However, the occurrence of mixed disulfides with low 
 
molecular weight compounds or intra-molecular disulfides, resulting in smaller changes in the 
 
molecular mass of intact proteins has been revealed by mass spectrometry. LC-ESI 
 
(light chromatography-electrospray ionization) or MALDI (Matrix-Assisted Laser Desorption/ 
 
Ionization) MS mapping experiments can detect mixed disulfides to specific Cys residues in 
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the polypeptide chain (Tell et al. 1998; Zheng Aslund and Storz, 1998; Vilardo et al. 2001; 
 
Cecconi et al. 2002). Irreversible oxidation of cysteine to sulfinic and sulfonic acids has been  
 
determined in intact protein molecules by using ESI-MS (Yang et al. 2002;  Woo et al. 2003).  
 
These products are stable and insensitive to treatment with reducing agents. The  
 
identification of those irreversible products of modified cysteines was obtained on protein  
 
digests by MALDI or LC-ESI and confirmed by tandem MS analysis (Rabilloud et al.2002;  
 
Yang et al. 2002). 
 
1.6.2 Oxidative Modification of Tyrosine 
 
Specific tyrosine derivatives produced by oxidation have been characterized for:  
 
myeloperoxidase-catalysed reaction pathways through the action of HOCl (Cl-Tyr, and 3,5 
 
-dichlorotyrosine, di-Cl-Tyr)  (Domigan et al. 1995, Fu et al., 2000; Podrez, Abu-Soud and 
 
Hazen, 2000), eosinophil peroxidase-catalyzed reaction pathways through the action of 
 
hypobromous acid (3-bromotyrosine, Br-Tyr, and 3,5-dibromotyrosine, di-Br-Tyr)  (Wu et al. 
 
199), and free radical pathways (o-Tyr, m-Tyr, and di-Tyr). Many tyrosine modifications rely  
 
on nitration rather than oxidation reactions in which peroxynitrite is commonly implicated as  
 
the principal mediator of tyrosine nitration. 
 
1.6.2.1 Possible Methods for Analysis of Oxidized Products of Tyrosine 
 
Cl-Tyr, di-Cl- Tyr, Br-Tyr, di-Br-Tyr, NO2–Tyr, and di-Tyr, have been all selected as amino  
 
acid products stable to acid hydrolysis, making them useful markers for protein oxidation/ 
 
nitration studies (Heinecke et al. 1999 b, c). On this basis, specific procedures for the 
 
detection of these derivatives in amino acid hydrolysates or biological fluids have been 
 
optimized by using direct HPLC quantification (Shigenaga et al. 1997) and GC (gas 
 
chromatography) or LC-MS analysis (Heinecke et al. 1999 b, c; Wu et al. 1999). 
 
However, methods for the detection of these modifications by direct ESI- or MALDI-MS 
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analysis of intact proteins or their peptide digests have found a positive application only in 
 
the case of NO2-Tyr-, or di-Tyr-containing proteins and Tyr radical species (Minetti et al. 
 
2000; Petersson et al. 2001; Sarver et al. 2001). The occurrence of intermolecular cross- 
  
linked di-Tyr residues in proteins following oxidative insult, to give macroscopic variation of 
 
protein molecular mass has usually been detected by low-resolution techniques such as  
 
SDS-PAGE under reducing conditions (MacMillan-Crow, Crow and Thompson, 1998; 
 
Lardinois, Medzihradszky and Ortiz de Montellano, 1999). 
 
1.6.3 Oxidative Modification of Methionine 
 
Met residues are highly susceptible to oxidation by almost all ROS (Vogt, 1995). Mild 
 
oxidizing conditions generate methionine sulfoxide, which can be further oxidized to  
 
methionine sulfone under stronger oxidizing conditions (Vogt, 1995; Levine, Moskovitz and   
 
Stadtman, 2000a). Methionine oxidation has been known to be associated with loss of  
 
protein function, as in case of alpha-1 antitrypsin, alpha-chymotrypsin actin & HIV-2 protease  
 
(Vogt, 1995; Davis et al. 2000; Dalle-Donne et al. 2002). However, Methionine oxidation  
 
does not cause loss of protein function in all cases (Levine et al. 1996). Interestingly,  
 
methionine oxidation can serve as an endogenous antioxidant defense, protecting the  
 
targeted proteins from more extensive irreversible oxidative damage at other essential amino  
 
acids (Levine et al. 1996; Levine, Moskovitz and Stadtman, 2000a) since it is enzymatically  
 
reversible. It has also been observed that, unlike other amino acid modifications, methionine  
 
modification has little or no effect on the susceptibility of proteins to proteolysis (Levine et al.  
 
1996 and Stadtman et al. 2002). 
 
1.6.3.1 Possible Methods for Analysis of Oxidized Products of Methionine 
 
The most ideal and easiest method for the detection of the methionine oxidation products  
 
such as sulfoxide and sulfone is ESI or MALDI mass spectrometry of intact molecular species 
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or protein digests (Hanson et al. 1999, 2000). Identification of modified methionine residues 
 
has been obtained in different proteins by LC-ESI or MALDI mass mapping experiments 
 
(Hanson et al. 1999, 2000; Taggart et al. 2000). Localization of an oxidative modification to a 
 
specific Met residue has been carried out by database searching (e.g. with MASCOT or 
 
SEQUEST) or by de novo sequencing (PEAKS) with reference to the known amino acid 
 
sequence of the protein (Ahmed et al., unpublished). 
 
1.6.4 Protein Carbonylation 
 
Protein carbonylation is an irreversible oxidative modification. Protein carbonyls are not  
 
repaired and are either removed by proteolysis or accumulate as damaged or unfolded  
 
proteins (Stadtman and Berlett, 1998). Protein carbonylation is an important marker of protein 
 
oxidation and is reported to be a good indicator of the extent of oxidative damage of proteins 
 
associated with various human diseases (Levine et al. 2000; Dalle-Donne et al. 2003c).  
 
The most common human diseases associated with carbonylated proteins are ARDS, 
 
Alzheimer’s disease, cataractogenesis, chronic renal failure, diabetes, pre-eclampsia,  
 
rheumatoid arthritis, ischemia, etc (Dalle-Donne et al. 2003). Carbonyl moieties (aldehydes  
 
and ketones) are produced on protein side chains, especially of proline, arginine, lysine and  
 
threonine, when these amino acids are oxidized into ketone or aldehyde derivatives (Berlett  
 
and Stadtman,1997). Protein carbonylation can also occur by reaction with various reactive 
 
products generated during lipid peroxidation, 4- hydroxynonenal (4-HNE), acrolein,  and  
 
malondialdehyde (MDA). However, carbonyls can be induced in vitro by almost all types of 
 
oxidants, including site-specific metal catalyzed oxidation, HOCl, γ-irradiation and Ozone 
 
(Shacter, E. 2000). 
 
1.6.4.1 Protein Carbonyls As Markers of Oxidative Stress 
 
Protein carbonyls have a major advantage over lipid peroxidation products as markers of 
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oxidative stress in that oxidized proteins are more stable. Carbonyls are formed early and 
 
circulate in the blood for longer periods (at least 4 hours in serum) (Pantke, U. et al. 1999), 
 
compared with other parameters of oxidative stress, such as glutathione disulfide and MDA. 
 
Protein carbonyls are present at low levels in most protein preparations (~1 nmol /mg protein) 
 
(Shacter, E. 2000). In vivo, under conditions of oxidative stress, 2- to 8- folds elevations of 
 
carbonyls is expected (Shacter, E., 2000). 
 
1.6.4.2 Possible Methods For Detection of Protein Carbonyls 
 
Carbonylated adducts can be detected either in protein and fluid hydrosylates by GC- and 
 
LC-ESI-MS analysis or by direct ESI- or MALDI-MS measurements of intact proteins or 
 
peptide digests (Peterson et al. 1998; Saraswathi, Nakanishi & Shimizu, 1999; Lapolla, 
 
Fedele and Traldi, 2000). As well, protein modification by 4-HNE can be monitored for intact 
 
proteins by ESI- or MALDI-MS analysis (Bennaars-Eiden, A. et al. 2002, Crabb et al. 2002, 
 
Alderton et al. 2003). Furthermore, protein carbonyls can be measured within a mixture of 
 
proteins after reaction with dinitrophenylhydrazine (DNPH) by using spectroscopy, ELISA, 
 
immunohistochemistry or Western blot analysis (Shacter, E. 2000). 
 
1.6.5 Oxidation Of Tryptophan 
 
Tryptophan residues can be oxidized by ionizing radiation and are not expected to be  
 
oxidized by metal-catalyzed oxidation because tryptophan is not typically a site for metal iron 
 
binding (Stadtman, 1993). Several tryptophan oxidation products including kynurenine (KYN) 
 
hydroxytryptophans (HTRP), N-formylkynurenine (NFK), and 3-hydroxykynurenine (3OH- 
 
KYN) have been detected (Finley et al. 1998). Finely and co- workers (1998) have reported 
 
oxidative tryptophan modification in α-crystallin of bovine lens. Interestingly, the tryptophan 
 
oxidation products are themselves photosensitizers and are able to generate ROS (Reszka  
 
et al. 1996), which led to the hypothesis that oxidative tryptophan modification might play an 
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important role in senile cataractogenesis (Specter, 1995). 
 
1.6.5.1 Possible methods for the detection of tryptophanyl oxidative modification products   
 
Tryptophanyl oxidation products have been detected in protein digests by using MALDI-MS 
 
(Finely et al.1998). Taylor et al. (2003) have reported the use of LC-MS/MS and ESI-MS for  
 
the detection of tryptophanyl oxidative products. 
 
1.6.6 Oxidation of Histidine 
 
2-Oxo-histidine and 4- or 5-hydroxy-2-oxo-histidine are generated from histidine oxidation  
 
(Schöneich, 2000). Aspargine, aspartate and HNE-His can also be generated from histidine 
 
oxidation (Shacter, 2000). Histidine has been identified as the amino acid most susceptible  
 
to metal-catalyzed oxidation (MCO) in vivo e.g. Cu, Zn SOD, and in vitro e.g. Cu, Zn SOD, 
 
glutamine synthetase, glycated insulin and LDL (Schöneich, 2000). Histidine oxidation has 
 
been reported as one of the most important markers of oxidative stress in vivo. 
 
1.6.6.1 Possible Methods For Detection of Oxidized Histidine products 
 
The presence of oxidized histidine derivatives can be ascertained by direct ESI or MALDI-MS 
 
analysis of intact molecules (Kurahashi et al. 2001; Schöneich and Williams, 2002). 
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1.7  Study of Ferritin and Transferrin as a Model of Oxidative  
  
           Modifications of Proteins 
  
This section describes aspects of the chemical structure, physiological and biochemical  
 
functions of ferritin and transferrin.  
 
1.7.1 Ferritin 
 
Ferritin is the principal protein involved in storing iron in a soluble, non-toxic, yet bioavailable 
 
form in bacteria, plants, and animals. Ferritin maintains up to 4500 atoms of hydrolyzed 
 
and polymerized atoms in a soluble form within a protein shell with a hollow interior of 
 
approximately 90 Ǻ (Hynes, M. et al. 2002; Welch, K. at el. 2002). 
 
Ferritin binds iron in a catalytically inactive manner; accordingly, oxidative reactions cannot 
 
be promoted by iron bound to ferritin. Because the main iron pool of most cells is located  
 
within the ferritin core, it is important to know under what circumstances this pool may  
 
become a source of free iron capable of causing oxidative damage (Rudeck, M. et al. 2000). 
 
Ferritin iron can be released by a variety of reducing agents [dihydroflavins, paraquat, iron 
 
chelators and, interestingly, superoxide ion] (Thomas Paul, 2000), due to their ability to 
 
reduce tightly bound iron (III) to the more mobile iron (II) form (Boyer et al. 1987; Thomas et 
 
al. 1986). Direct chelation of iron (III) may also mobilize iron from ferritin with or without 
 
reduction to iron (II). In the absence of chelators, the reduced core of ferritin iron appears to 
 
remain within the protein shell (Hynes et al. 2002). However, ferritin has been shown to 
 
release iron on contact with activated microglia and neutrophils by a superoxide-dependent 
 
mechanism (Rudeck, M. et al. 2000). Once oxidative damage occurs to ferritin under the 
 
effect of any of the above-mentioned circumstances, the ferritin molecule undergoes some 
 
physiological malfunctions such as release of iron and possible damage of the apoferritin 
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molecule (Rudeck, M. et al. 2000). Hydrogen peroxide-induced protein oxidation enhances 
 
the proteolytic susceptibility of the damaged ferritin (Davies, K. et al. 1987; Reinheckel, T. et 
 
al. 1998; Grune, T. et al. 1995). Mammalian ferritin consists of a protein shell with 24  
 
subunits surrounding a core of ferrihydrate, each subunit weighing either 19 766 kDa (the L 
 
subunit) or 21 099 kDa (the H subunit) (Hynes et al. 2002; San-Marina, S. et al. 1995 and 
 
Theil, 1987). In normal human subjects, 25% of the total body iron is found in ferritin. Brain 
 
ferritin has 60-70% H subunit content, while horse spleen ferritin and mammalian liver  
 
ferritin consists predominantly of L subunits. Brain ferritin has been reported to have iron 
 
saturation of 1500 iron atoms per ferritin molecule (Hynes et al. 2002; Fleming et al. 1987;  
 
Dedman et al. 1992). Ferritin may play an important role in ameliorating metal toxicity when  
 
the brain is exposed to high levels of toxic metals. The increase in brain iron associated with  
 
several neurodegenerative diseases may lead to an increased production of free radicals,  
 
mostly of the hydroxyl radical (· OH) via the Fenton reaction. However, depending on the  
 
availability of free iron, the Fenton reaction can be directed as shown in the following formula: 
 
                                     SOD 
O¯2 (superoxide ion)- - - ----Æ H2O2 
 
             Catalase & Reduced Glutathione 
H2O2------ ---------------------Æ  H2O   OR  ·OH (whenever free iron is available). 
 
As shown, O¯2, under the action of superoxide dismutase (SOD) is converted into H2O2  
 
(hydrogen peroxide), which may be converted into water in the presence of catalase and  
 
reduced glutathione or into the fatal hydroxyl radical (·OH) whenever free iron is available. 
 
It is believed that iron loads into ferritin spontaneously, dependent upon a “ferroxidase 
 
activity “of the H subunits of ferritin (Welch et al. 2002). Loading iron into ferritin via its  
 
ferroxidase activity could damage the ferritin and any other biomolecules in close proximity  
 
as reported by Welch and co-workers, 2002.  
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According to the method of Silva, D. et al. (1992), the loading of apoferritin with ferrous 
 
ammonium sulfate was dependent on buffer, pH and the presence or absence of chelator, 
 
and was directly related to the rate of iron autoxidation. These authors indicated that iron 
 
loading into ferritin core resulted in depletion of the basic amino acids lysine and histidine, 
 
probably as a result of protein oxidation, as well as release of more iron than other methods 
 
for iron incorporation. Silva, D. et al. (1992) reported that buffers such as, MOPS, or the 
 
Good’s buffers, which are poor chelators of iron, allow rapid autoxidation of Fe (II) at pH 7.0. 
 
They have proposed that ferrous iron forms a complex with apoferritin prior to oxidation and 
 
incorporation, since ferric iron presented to the apoferritin under identical conditions does not 
 
result in incorporation. HEPES buffer, which is also a poor chelator of iron, allows the  
 
greatest oxidation of ferrous iron since it does not compete well, either with the protein for  
 
metal binding, or with water for coordination to free sites on the metal. When ferrous 
 
ammonium sulfate was incubated with ferritin in HEPES buffer at pH 7.0, the initial rate of  
 
iron incorporation was approximately 10-fold greater than when the experiment was repeated 
 
at pH 6.0. It should be noted that, as the pH decreased, the stability of Fe (II) increased  
 
which may hinder the hydrolysis and autoxidation because of the lack of the deprotonation of 
 
iron-bound water molecules (Silva, D. et al. 1992). 
 
1.7.2 Transferrin 
 
The transferrin family (Trf) constitutes the major iron transport and /or scavenging system in 
 
vertebrates and some invertebrates (Aisen, 1998). However, Trf can also function as an 
 
iron chelator, which contributes to host defense by limiting iron availability for microbial 
 
pathogens. This capacity to bind iron also enables transferrin to protect cells from oxidative 
 
damage. ·OH radical generated from ¯O2 and H2O2 via the Haber-Weiss reaction has been 
 
suggested to be an important contributor to phagocyte- mediated tissue injury and other free 
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radical associated processes. Trf is a soluble glycoprotein and a bilobal molecule i.e. it  
 
contains an N-terminal (amino acids 1-336) and a C- terminal (amino acids 337-679) globular  
 
domain. Each domain contains a metal-binding site and each lobe binds one iron atom.  
 
Under normal conditions, these two high-affinity-iron binding sites, prevent the existence of  
 
measurable amounts of unbound iron in the plasma. The main source of iron for transferrin is  
 
catabolism of non-viable red blood cells and its main destination is the erythroid marrow.  
 
Amino acid sequences of transferrins from several species, including human, bovine, rabbit,  
 
and chicken, show a high degree of sequence similarity (Thevis, M. et al. 2003). Serum-  
 
transferrins and ovotransferrins transport iron from neutral biological fluids to the cytoplasm  
 
by receptor-mediated endocytosis (El-Hage Chahine, et al. 1999; Dautry Varsat et al. 1983).  
 
In contrast, lactoferrins and again ovotransferrins behave as bacteriostatic iron scavengers  
 
(Moore et al. 1997; Kurokawa et al. 1995). As we have mentioned earlier, free iron is capable  
 
of stimulating the production of free radicals which cause oxidative damage such as lipid  
 
peroxidation. Trf is one of the most important antioxidants, and acts by sequestration of iron  
 
in a redox-inactive form (van Campenhout, A. et al. 2003). Apotransferrin, at physiological  
 
concentrations (2-3 mg/ml) is known to inhibit lipid peroxidation in the liposome model by  
 
iron-binding (Van Campenhout et al. 2003). However, at higher concentrations, 
 
apotransferrin does not inhibit lipid peroxidation any further, while at low concentrations, 
 
apotransferrin reduces antioxidant capacity in a concentration-dependent manner. This 
 
finding is clinically relevant in diseases that are associated with lower plasma transferrin 
 
concentrations as a result of either a decreased synthesis or increased breakdown (Van 
 
 Ca penhout et al.2003). Trf is a negative acute-phase protein which is downregulated 
 
in inflammatory diseases such as diabetes. Moreover, oxidative damage results in protein 
 
fragmentation and nephropathy which can lead to loss of transferrin in the urine of type 1 and 
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type 2 diabetic patients. Interestingly, microtransferrinuria seems to be a more sensitive index 
 
for renal dysfunction than microalbuminuria (Campenhout,et al. 2003). Keenoy et al. (2005) 
 
have also reported that inhibition of lipid peroxidation by transferrin was almost total in the  
 
presence of 60 μM iron, a concentration that saturates transferrin completely (100%  
 
transferrin saturation).  
 
1.7.2.1 NTBI (Non-transferrin bound iron)  
 
Plasma transferrin has considerable reserves for coping with increasing amounts of incoming 
 
iron, but these may be exceeded in certain pathologic diseases. In acute iron poisoning, the 
 
concentration of NTBI ranging from 128 µM to over 800 µM have been documented,  
 
exceeding the total iron binding capacity of transferrin (Reynolds and Klein, 1985).  
 
Buchanan (1971) has reported acute episodes of abdominal pain and shock in association  
 
with extremely high serum iron measurements ranging from 214 µM to 2200 µM in severe  
 
idiopathic hemochromatosis patients. NTBI is weakly complexed to albumin, citrate, amino  
 
acids and sugars , and behaves differently from iron associated with transferrin. Lehotay, D. 
 
et al. (2001) have indicated that patients with HH (hereditary hemochromatosis), but not other  
 
groups with iron overload status, exhibit higher than normal levels of NTBI as compared to  
 
control groups without hemochromatosis.  
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1.8 Hydrogen Peroxide (H2O2) As an Oxidizing Agent in Biological 
 
         Systems 
 
Hydrogen peroxide is generated in all aerobic organisms as a result of normal cellular  
 
metabolism. Hydrogen peroxide is known to be produced during photosynthesis, and during 
 
phagocytosis as well; it can also be detected in human expired air. It can penetrate cell 
 
membranes rapidly whereas superoxide ion usually cannot. Once inside the cell, it can react 
 
with Fe (II) or Cu (I) via Fenton reaction. Hydrogen peroxide is being continuously generated 
 
and destroyed. The liver has the most effective mechanism for disposing of hydrogen  
 
peroxide. Other tissues such as lens of the human eye and rabbit spermatozoa have less 
 
effective hydrogen peroxide-removal mechanisms that causes release of it into the  
 
surrounding media (Cutteridge et al. 1985). Thus, electrons that leak from the electron  
 
transport chain of mitochondria cause the univalent reduction of molecular oxygen to  
 
superoxide anion (O2˙¯), which is then spontaneously or enzymatically dismutated to H2O2  
 
(Kim et al. 2000). Hydrogen peroxide is also generated by lipoxygenase, xanthine oxidase, 
 
and cytochrome P450, as well as in the cellular response to ultraviolet radiation (Kim et al., 
 
2000). There are also several enzymes that produce hydrogen peroxide without  
 
intermediacy of free O¯2 radical. These include glycollate oxidase, D-aminoacid oxidase, and  
 
urate oxidase (Cutteridge et al. 1985). Furthermore, many cell types produce hydrogen  
 
peroxide in response to a variety of extracellular stimuli including cytokines, peptide growth 
 
factors, neurotransmitters, hormones and (Kim, et al. 2000). 
 
Hydrogen peroxide is readily converted to hydroxyl radical (˙OH), as mentioned above, via  
 
the Fenton reaction in the presence of iron (or copper) and cellular reductants, and these 
 
radicals induce irreversible oxidative damage to various cellular components (Kim et al.  
 
2000).Two enzymes are known to be involved in protecting living cells against hydrogen 
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peroxide:catalase and peroxidase. Catalase catalyzes the breakdown of hydrogen peroxide 
 
into water and oxygen. Catalase activity can be inhibited by azide or cyanide and importantly,  
 
aminotriazole, which when fed to rabbits inhibits catalase activity causing the concentration of  
 
hydrogen peroxide to increase leading to an accumulation of hydrogen peroxide in the lens,  
 
inducing cataractogenesis. Glutathione peroxidase cannot by itself prevent the hydrogen  
 
peroxide generation (Cutteridge, et al. 1985). Glutathione peroxidase exerts its action as  
 
scavenger of hydrogen peroxide by catalyzing the oxidation of GSH to GSSG (Cutteridge et  
 
al. 1985). Since the O-O bond is relatively weak, hydrogen peroxide decomposes easily by  
 
homolytic fission to give rise to the hydroxyl radical. It mixes readily with water, and its  
 
oxidizing action gives it some antibacterial properties when used in high concentrations  
 
(Cutteridge et al. 1985).  
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1.9 Mass Spectrometry As an Analytical Technology 
 
Mass spectrometry has become an important technique to study protein sequence and  
 
structure. This has been achieved, in part, by improvements in ionization and mass analysis  
 
techniques concurrently with large-scale DNA sequencing of whole genomes (Yates, 1998).  
 
Mass spectrometry can measure the masses of atoms or molecules that have been  
 
converted into ions. As shown in Fig.1, a generic mass spectrometer consists of: 
 
• Inlet: through which the sample (solid, liquid or gas) is introduced into a vacuum  
 
               chamber. 
 
• Ion Source: in which the sample is ionized. 
 
• Mass Analyzer: in which ions are separated according to their mass-to-charge (m/z)  
 
      ratios. 
 
• Detector: in which the ions generate an electrical signal that is proportional to the  
 
     number of ions. 
 
• Data Analysis System: which records these electrical signals and then converts  
 
     them into a mass spectrum (a plot of relative ion abundance vs. m/z ratio). A good 
 
     mass spectrum should contain sharp, symmetrical, and well defined peaks and have  
 
     an acceptable resolution and signal-to-noise ratio. 
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Fig.1: Schematic diagram of a Voyager-DE STR MALDI-TOF mass spectrometer  
 
         (Applied Biosystems) 
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1.9.1 Key Technologies In The Study of Proteins 
 
1.9.1.1 One-Dimensional Polyacrylamide Gel Electrophoresis (1-D PAGE) 
 
The separation of proteins at this stage is based on differences in molecular weight.  
 
1.9.1.1 Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS) 
    
This technique provides rapid identification of PAGE or affinity-purified proteins by mass  
 
analysis and database matching of component peptides. MALDI-MS is normally used to  
  
analyze relatively simple peptide mixtures. Peptide mass mapping can positively identify a 
 
protein of known sequence if peptide masses match to within 50 PPM and if the protein 
  
sequence coverage is at least 15%. MALDI uses a pulsed UV to desorb and ionize 
  
compounds that have been co-crystallized in a UV-absorbing matrix (Fig.2). 
 
MALDI works with a time-of-flight (TOF) analyzer that measures the masses of intact  
 
peptides. TOF analyzers have 2 modes of operation; Linear, which is more sensitive with 
  
lower mass resolution; and Reflectron, which is less sensitive with higher mass resolution. 
  
When acquiring data, there are some factors that contribute to the accuracy of mass 
 
measurements: 
 
1. Symmetrical peak shape: Depending on the m/z in question, the spacing  
 
      between data points can represent a change in mass from 10 to 20 ppm to  
 
      more than 100 ppm. 
 
2. Signal-to-noise ratio as high as possible without skewing peak shape:  
 
      peak position can be affected by noise or by saturation of the detector. 
 
3. Signal intensity of reference and analyte peaks above m/z 1,000: Needed for  
 
      accurate assignment of peak position. 
 
4. Signal intensity of reference and analyte peaks should be in the same range. 
 
5. No contaminants should be present. 
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6. Two internal reference masses that bracket the mass range of interest. 
 
Most instruments (e.g. Voyager-DE STR, Applied Biosystems ) have software that includes a  
 
default calibration routine that provides adequate mass accuracy for many applications. The  
 
calibration function in the Voyager (Data Explorer) software allows the generation of  four  
 
types of calibrations: 
 
1. Default calibration: provides typically 0.1% accuracy in Linear Mode, and 
 
      typically 0.01% or better accuracy in Reflector Mode. 
 
2. External calibration: Provides 0.05% accuracy in Linear mode, and 0.01% 
 
       or better accuracy in Reflector Mode. 
 
3. Internal calibration: Provides accuracy of 0.02% or better in Linear Mode, and 
 
       0.002% (20 ppm) in Reflector Mode. 
 
4. Sequence control calibration: Provides external, internal, and internal with 
 
      automatic updating calibration options during acquisition from the Sequence 
 
      Control Panel. 
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Fig.2: Mechanism of desorption and ionization during MALDI 
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1.9.1.2 Electrospray Ionization Tandem Mass Spectrometry (ESI-MS/MS) 
 
ESI-MS/MS allows proteins and posttranslational modifications (PTMs) to be identified by  
 
sequence analysis of component peptides. ESI-MS/MS systems are preferred for the  
 
analysis of complex samples. ESI-MS/MS sequencing is also used when peptides cannot  
 
be matched to proteins in existing databases (Wilm et al. 1996). ESI-MS/MS can be  
 
performed using ion trap and tandem quadrupole instruments, and is used to generate  
 
fragmentation spectra (CID spectra) of selected precursor ions. In this study, our samples 
 
were analyzed by LC-MS/MS using a capLC ternary HPLC system (Waters, Milford, MA, 
 
USA) interfaced to a Q-TOF Ultima Global hybrid tandem mass spectrometer fitted with a Z- 
 
 spray nanoelectrospray ion source (Micromass, Manchester, UK). To maximize the  
 
 formation of peptide ions by ESI, separations are best conducted at low pH (Ross, A. 1998). 
 
 The purpose of using tandem mass spectrometer (MS/MS) is to generate fragment ions from 
 
 parent ions to provide structural information about a given molecule, as used in our in vitro  
 
 and in vivo ferritin and transferrin oxidation experiments. Tandem mass spectrometry also 
 
 allows for identification of compounds in complex mixtures. This is also demonstrated in our 
 
  in vivo experiments which dealt with plasma samples from patients with hereditary  
 
  hemochromatosis, since our protein of interest (transferrin) was identified among several  
 
  plasma proteins. Different MS/MS configurations include; Quadrupole- quadrupole (low  
 
  energy),Magnetic sector-Quadrupole (high energy), Q-TOF (low energy) and TOF-TOF 
 
  (high energy). 
     
  1.9.1.3.1 MS/MS for protein ID 
 
  Proteins of interest are isolated from gel and subjected to tryptic digestion. Trypsin cleaves  
 
  at the C-terminal side of lysine and arginine. Peptides are sent through the ionizer and into 
 
  a collision cell where singly or multiply charged ions are selected and fragmented through 
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 collision induced dissociation (CID). The resulting fragment ions are analyzed to determine  
 
 the sequence or to identify the parent peptide. CID of peptides less than 2-3 KD is most  
 
 efficient for MS/MS studies. The frequency of tryptic cleavage sites guarantees that most 
 
 peptides are of this size. Protein ID using peptide CID spectra is more specific than that 
 
 achieved by mass mapping because, in addition to the peptide mass, the peak pattern in the 
 
 CID spectrum also provides information about peptide sequence. 
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Fig. 3: Schematic diagram of Quadrupole-Time-OF-Flight (Q-TOF) Tandem Mass 
 
Spectrometer 
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1.9.1.3.2 Peptide fragments and daughter ions 
 
Peptides, once admitted to the collision cell, usually fragment at the weakest bond (the  
 
peptide bond) although some CH-NH and CH-CO cleavage also occurs. Peptides do not  
 
fragment sequentially, that is to say, the first fragmentation event does not start at the amino  
 
terminus and proceed sequentially one residue at a time down the amino acid chain. The  
 
fragmentation events are somewhat random and not necessarily sequential. In addition,  
 
some fragmentations are preferred over others. Upon fragmentation, two main types of  
 
daughter ions are produced; b- and y- ions. These are the most common types of daughter  
 
ions. 
 
During CID, peptides are preferentially fragmented along the peptide backbone. Six types of  
 
fragment ions that may be generated. These include a, b and c, if the charge is located at the 
 
N-terminus and to fragments of type x, y and z if the charge is located on the C-terminus.   
 
Any position in the peptide backbone can be fragmented including alkyl-carbonyl bonds  
 
(CHR-CO), producing a and x ions, peptide-amide bonds (CO-NH), producing b and y ions  
 
and amino-alkyl bonds (NH-CHR), producing c and z ions. Cleavage of amide bonds is most 
 
common generating b- and y-type ions. Additional fragment ions resulting from the loss of  
 
water, carbon monoxide or ammonia can also be generated during CID and facilitate the  
 
identification of specific amino acid within a spectrum (Schweppe et al., 2003). 
 
1.9.1.3.3 MS/MS sequencing and calculation of b- and y- ions masses 
 
It is not always easy to differentiate between b- and y-ion. Because trypsin cuts after lysine  
 
or arginine, we can assume that  y1 corresponds to one of these two residues. The m/z of y1 
 
is calculated by adding 19.018 u (three hydrogens and one oxygen) to the residue masses of 
 
lysine or arginine. y2 can be calculated using the same method by finding another prominent 
 
peak that is equal to y1 + AA, where AA is one of the known residue masses for each of the 
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20 common amino acids, and so on for each yn. Hence, the yn series produces a reverse 
 
sequence of the peptide. b-ions can be constructed using the same strategy. The fragment 
 
containing only the amino terminal amino acid is termed b1. The b1 fragment is seldom 
 
observed making it difficult to determine the order of the first two N-terminal amino acids 
 
in a peptide sequence. The fragment containing the first two amino terminal amino acids is 
 
termed the b2 ion, and so forth. Once the mass of a b or y ion is determined, the  
 
corresponding y or b ion can be calculated using the following formulas: 
  
y = (M+H)1+ - b +1 
-  
b = (M+H)1+ - y +1 
 
1.9.1.3.4 Different MS/MS instruments yield different spectra  
 
A typical Q-TOF or Triple quad MS/MS spectrum of a tryptic peptide contains a continuous  
 
series of y-type ions. The b-type ions are usually seen only at lower masses below the 
 
precursor m/z value. Ion trap CID data of tryptic peptides contains a continuous series of  
 
both b-type and y-type ions throughout the spectra. 
 
1.9.1.4 High Performance Liquid Chromatography (HPLC) 
 
Increases sensitivity and sequence coverage for ESI-MS/MS by providing on-line separation  
 
of peptide mixtures. 
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Fig: 4: The formation of the charged droplets by Electrospray. 
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1.9.1.5 PEAKS Software 
 
This software can be used to interpret peptide MS/MS data directly and/or correlate it with  
 
sequences in databases. The rapid increase in the number of protein sequences in these  
 
databases have greatly aided the analysis of tandem mass spectra of peptides, since  
 
deducing peptide sequences from raw MS/MS data is tedious and slow when performed  
 
manually. The most popular software used to search databases of known genomes with  
 
the uninterpreted MS/MS data are Mascot and Sequest. These algorithms are effective 
 
but often give false positives or incorrect identification (Ma, B. et al. 2003).  
 
Searching database with partial sequences (sequence tags) derived from MS/MS data gives 
 
more reliable results (Mann, M. et al. 1994). The de novo sequencing software package, 
 
PEAKS, has the advantage of extracting amino acid sequence information without the use of 
 
databases. PEAKS uses a new model and a new algorithm to efficiently compute the best 
 
peptide sequences whose fragment ions can best interpret the peaks in the MS/MS  
 
spectrum.  
 
The output of the software gives amino acid sequences with common and user-defind   
 
posttranslational modifications, as well as an additional novel positional scoring scheme for  
 
entire and partial sequences (Ma, B. 2003).  
 
PEAKS has been used to successfully compute the sequences of peptides, and is a very  
 
useful tool for the analysis of proteomes of both known and unknown genomes. 
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1.10 Hereditary Hemochromatosis  
 
Iron overload is a common problem found in clinical practice. Iron overload can be either  
 
primary (as a result of an inherited metabolic disorder) or secondary to another problem that  
 
results in iron absorption (Harrison S. et al. 2003). The most common cause of primary iron  
 
overload is hereditary hemochromatosis (HH). However, among secondary iron overload  
 
causes are iron-loading anemias e.g. Thalassemia major, Sideroblastic anemia, chronic  
 
hemolytic anemia and aplastic anemia. Moreover, red blood cell transfusions, iron-dextran  
 
injections, long term hemodialysis, porphyria cutanea tarda, hepatitis C and B non-alcoholic  
 
steatohepatitis, aceruplasminemia and congenial atransferrinemia are possible causes for  
 
secondary iron overload (Harrison, S. et al. 2003). 
 
1.10.1 History 
 
The term ‘hemochromatosis’ was first used by von Recklinghausen, a German pathologist in  
 
the late 1800s (Recklinghausen, V. et al. 1889); he determined that the pigmentation seen in 
 
patients with advanced hemochromatosis was due to iron. In 1935, Joseph Sheldon, a British 
 
geriatrician, published a monograph describing over 300 cases with hemochromatosis, 
 
concluding that the disorder was an inherited defect caused by excess iron (Sheldon, J.  
 
1935).    
 
 In mid-1970s, Simon and colleagues in northern France confirmed that hereditary  
 
hemochromatosis (HH) was inherited as an autosomal recessive disorder linked to the short  
 
arm of chromosome 6 in the region of HLA-A3 (Simon, M. et al. 1977). Finally, in 1996, a  
 
team of molecular geneticists in California discovered the gene responsible for HH (Feder, J. 
 
et al. 1996). It was first called HLA-H and was later named HFE (Harrison, S. et al. 2003). 
 
1.10.2 HFE gene and protein 
 
As mentioned above, Feder and colleagues used a positional cloning technique to identify a 
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novel gene called HFE in the HLA region of chromosome 6 (Feder, et al. 1996 and Harrison 
 
et al. 2003). This gene encodes a MHC class 1-like protein that binds to β2-microglobulin  
 
(β2M) and that interacts with TfR-1 (Enns, et al. 2001 and Lebron, et al. 1998).  
 
Uncomplexed HFE protein is rapidly degraded (Whittington, et al. 2002) HFE and transferrin 
 
competes for overlapping binding sites on TfR (Proceeding of BioIron, 2002). Interaction 
 
between HFE and TfR is probably necessary in the normal control of iron absorption, as 
 
compound mutant mice hemizygous for TfR and HFE -/- accumulate more liver iron than HFE 
 
-/- mice alone (Harrison, et al. 2003 and Levy, et al. 1999). HFE protein has a large  
 
extracellular domain, a single transmembrane region, and a short cytoplasmic tail. Two  
 
missense mutations were identified in HFE (Feder, et al. 1996 and Harrison et al. 2003). The 
 
most common one (C282Y) results in the change of a cysteine to a tyrosine at amino acid  
 
position 282. This amino acid substitution prevents the binding of HFE protein to β2M by  
 
disrupting a disulfide bridge in the extracellular domain and thereby decreases the amount of  
 
HFE protein expressed on the cell surface (Enns et al. 2001; Britton et al. 2002; Trinder et  
 
al. 2002, and Lebron et al. 1998). Failure to interact with β2M impairs HFE protein processing, 
 
transport, folding and cell surface expression (Waheed et al. 1997). Numerous studies have  
 
confirmed that approximately 85% of typical HH patients from around the world are  
 
homozygous for C282Y (Bacon et al. 1999 and Adams et al. 2000). In the original work  
 
conducted by Feder and colleagues, 83% of 178 phenotypic HH patients were found to be  
 
homozygous for the C282Y mutation Feder et al. 1996 and Harrison et al. 2003). The second 
 
mutation in HFE results in a change in histidine to aspartate at amino acid position 63 (H63D)  
 
and is found in 15-20% of the general population (Bacon et al. 1999 and Adams et al.  
 
2000).This mutation doesn’t inhibit the binding of HFE protein to β2M, and individuals who are  
 
homozygous for the H63D mutation have only mild iron accumulation (Gochee et al. 2002). 
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However, some individuals who carry both the C282Y and H63D mutations (compound  
 
heterozygotes) have clinically significant iron overload (Harrison et al. 2003; Bacon et al.  
 
1999 and Adams et al.2000). HFE knockout mice studies validated the importance of HFE in  
 
the development of iron overload, providing evidence that these HFE knockout mice have  
 
increased iron absorption, elevated transferrin saturation levels and increased hepatocellular  
 
iron storage similar to humans with HFE- linked HH (Zhou et al. 1998 and Bahram et al.  
 
1994). 
 
1.10.3 Pathophysiology of HH 
 
The primary defect in HFE-related HH is an increase in intestinal iron absorption relative to 
 
body iron stores (Harrison et al. 2003). Normally, total body iron content ranges from 3-5 g, 
 
and 20-30 mg of iron are recycled daily, mainly through phagocytosis of senescent  
 
erythrocytes by macrophages (Andrews, 1999). Only 1-2 mg of iron /day are typically lost  
 
from the body, and females have an increased physiologic loss of iron through menstruation. 
 
Accordingly, 1-2 mg of iron are absorbed daily from the diet to maintain normal iron  
 
homeostasis (Andrews, 1999). The cells of the intestinal epithelium in the duodenum and 
 
proximal jejunum are responsible for absorbing iron from the diet (Fletcher et al. 2002). Iron 
 
enters crypt cells of the duodenum from the circulation by transferrin-mediated endocytosis 
 
involving HFE protein, iron-laden transferrin and TfR (transferrin receptor). Crypt cells sense 
 
body iron requirements and are programmed with this information as they mature into villous 
 
cells (mature enterocytes), which absorb dietary iron. Non-heme ferric iron (Fe III) is  
 
reduced to ferrous iron (Fe II) by Dctyb protein and is transported into the cells by DMT1.  
 
Iron may be either stored in the cytoplasm of the villous as ferritin, or exported into the  
 
circulation laden by transferrin through Ireg1 with the aid of hephaestin (Heph) which  
 
functions as a ferroxidase, oxidizing Fe II into Fe III. Transferrin transports Fe III in the 
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circulation to sites of utilization, particularly the erythrocyte precursors in the bone marrow.  
 
Macrophages of the reticuloendothelial system take up iron via transferrin-receptor  
 
mediated endocytosis and recycle iron from senescent red cells back into circulation. In the  
 
liver, hepatocytes acquire iron from various sources including receptor-mediated endocytosis  
 
via TfR1 and the TfR2. DMT1 may be involved in the entry of nontransferrin bound iron  
 
(NTBI) into hepatocytes. Within the endosome, acidification results in iron release from the  
 
receptor Iron may be stored as ferritin until required. The liver is the main storage site for iron  
 
as ferritin (Fletcher et al. 2002). The released iron is once again accepted by transferrin to be 
 
transported in the circulation. Based on the previously mentioned information, iron  
 
homeostasis is regulated under the umbrella of two regulators (sensors), ‘erythroid regulator’ 
 
and ‘iron stores regulator’ (Fletcher et al., 2002). The ‘erythroid regulator’ has much greater 
 
control over iron absorption because of the high demand for iron from these cells, which must 
 
be met on a daily basis. The regulatory signal is sent to the liver and other storage sites to  
 
stimulate the rapid mobilization of iron for erythropoiesis. Following the depletion of iron  
 
stores from storage sites, the proposed ‘stores regulator’ stimulates pathways responsible for 
 
the slow absorption of iron from the diet. This signal has to be controlled to prevent excessive 
 
absorption (Sayers et al., 1994). Hepcidin is another component of the ‘store regulator’  
 
expressed in the liver and induced by iron. It acts to down regulate iron absorption (Andrews, 
 
1999 and Harrison et al. 2003). 
 
1.10.4 Diagnostic criteria and treatment 
 
The first step in the definitive diagnosis of HH is the use of phenotypic tests of iron overload. 
 
The ‘gold standard’ is transferrin saturation (serum iron divided by transferrin) (Fletcher et al. 
 
2002). Some other markers are also used e.g. UIBC (unsaturated iron binding capacity),  
 
TIBC (total iron binding capacity) (Sayers et al. 1994). Serum ferritin and liver enzymes 
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(particularly ALT) are also useful when the patient is being considered for liver biopsy. So  
 
far, two categories of patients can be identified, asymptomatic and symptomatic patients 
 
(Fletcher et al. 2002). Asymptomatic patients present with abnormal serum iron whilst 
 
symptomatic patients usually present with fatigue, diabetes mellitus, skin pigmentation, 
 
hepatomegally, hypogonadism, arrhythmia and arthopathy (Tavil, 2001). However, patients  
 
may also be evaluated following family or population screening using phenotypic and/or 
 
genotypic methods (Tavil, 2001). Genetic studies usually involve analysis for both the C282Y  
 
mutation and H63D in HFE. If the subject is C282Y homozygous, with elevated transferrin  
 
saturation and/or serum ferritin and/or elevated liver function tests, liver biopsy should be  
 
considered. Furthermore, if the serum ferritin exceeds 300 µg L¯¹ in males or 200µg L¯¹ in  
 
females and continues to rise, venesection therapy should be started (Fletcher et al. 2002).  
 
Regular venesections of 500 mL (250 mg iron)/treatment should be continued until the  
 
hemoglobin begins to fall and does not rise again immediately after venescetion ceases.  
 
Serum ferritin should fall below 50 µg L¯¹. If the subject is C282Y homozygous with normal  
 
transferrin saturation, serum ferritin should be measured annually and venesection therapy  
 
considered if these markers become elevated. For those subjects who are heterozygous for  
 
the C282Y mutation or compound heterozygous (heterozygous for both C282Y and H63D  
 
mutations), liver biopsy should be considered using the same criteria. Moreover, some other  
 
co-factors should be considered e.g. steatohepatitis, excess alcohol consumption or chronic  
 
viral hepatitis. Those with normal iron should be counseled. Similar considerations should be  
 
given to those subjects who are C282Y normal or homozygous for the H63D mutation  
 
(Fletcher et al. 2002). 
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2.0 Hypothesis 
 
We hypothesized that disrupting iron homeostasis plays a role in free radical injury and leads 
 
to oxidative modifications and possible loss of function of ferritin and transferrin in hereditary 
 
hemochromatosis (HH) when free iron or non-transferrin-bound iron (NTBI) concentrations  
 
rise and iron-binding proteins become saturated.  
 
3.0 Rationale 
 
This study was conducted to shed light on the role of oxidative modifications of ferritin and 
 
transferrin and to determine the nature of such oxidative damage in hereditary  
 
hemochromatosis (HH). Iron overload in HH may lead to oxidation of these proteins that  
 
could cause a loss of function. 
 
Such information will provide insight into the structure–function relationship of these  
 
proteins, and may improve our understanding of the altered role of these oxidatively 
 
modified proteins. 
 
4.0 Objective of the Study 
 
• Validation of the methods. 
 
• Comparative analysis of ferritin and transferrin in plasma from normal individuals and  
 
      HH patients. 
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5.0 Materials and Methods 
   
5.1 ‘Gel-free’ Protein Digest Experiment 
 
The purpose of this experiment was to demonstrate ‘gel free” protein digestion while  
 
confirming the identities of commercial standard proteins (ferritin and transferrin) by peptide  
 
mass fingerprinting using MALDI-TOF/MS. Proteins were analyzed without exposure to  
 
oxidative stress. This experiment had two stages: Poroszyme Method for Protein  
 
Digestion and MALDI-TOF MS to identify the proteins by peptide mass fingerprinting. 
 
We used 60 ng of the ferritin standard (150 femtomole of protein), and 6 ug of the  
 
transferrin standard (~ 78 picomole). These quantities represent, respectively, 100 times 
 
and 0.006 times the minimum amounts of ferritin and transferrin normally found in 50uL of 
 
human plasma (the volume of sample used later for immunoprecipitation of these proteins  
 
from human plasma samples). Page 45. 
 
5.1.1 Poroszyme™ Method for Protein Digestion 
 
1. Approximately 100 µL of sample was dried down on a speed vac at 35º C for ~ 1½  
 
      hrs. 
 
2. The dried sample was dissolved in 100 µL using 100 mM ammonium bicarbonate  
 
      buffer containing 60 mM dithiothreitol as a reducing agent.   
 
3. The mixture was heated for 1 hr at 45º C.  
 
4. Iodoacetamide was added in ammonium bicarbonate buffer to a final concentration of 
 
190 mM. 
 
5. The samples were heated for 1 hr at 37ºC in dark. 
 
6. 5 μL of Porozsyme beads (immobilized trypsin) were added to each sample and 
 
      vortexed for 1 hr. 
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7. The samples were centrifuged to pellet beads for 10 min at 10,000 g. 
 
8. The supernatant was transferred to a new tube; without disturbing the beads. 
 
9. 10 μL were transferred to a smaller tube for solid-phase extraction using Millipore Zip  
 
      Tips 
 
10.  10 μL 1% TFA in water was added to each. 
 
11.   Using Millipore Zip Tip* - C18 reversed phase (size P10) and a 10 μL pipette: 
 
• Aspirate with 75% ACN with 0.1% TFA. Dispense to waste 3 x 10 μL  
 
• Aspirate with 0.1% TFA in water. Dispense to waste 3 x 10 μL. 
 
• Samples were aspirated and dispensed in tubes 5 to 10 times. Tips were 
 
      blown out.  
 
• Tip was washed with 75% ACN with 0.1% TFA. Aspirate and dispense to waste 
 
5 x 10 μL. 
 
• Aspirate with α C matrix (5 mg/ml in 75% ACN with 0.1% TFA) to first indent on  
 
tip. 
 
• Dispense onto plate target spot and mix, avoid forming bubbles on plate. 
 
*ZipTip is a 10 µL pipette tip with a 0.6 or 0.2 µL bed of chromatography media fixed at its  
 
end with no dead volume. It is ideal for concentrating and purifying peptides or proteins in  
 
seconds prior to mass spectrometry, HPLC, capillary electrophoresis and other analytical  
 
techniques 
 
5.1.2 MALDI-TOF MS 
 
Peptide Mass Fingerprinting (PMF) analysis of the digested peptide samples was carried  
 
out on an Applied Biosystems Voyager DE-STR (Foster City CA) equipped with a nitrogen 
 
laser operated at 337 nm, 3 ns pulse. The instrument was operated in positive ion reflectron 
 
  
 
                                                                    
 
                                                                              
 
39 
 
mode. The samples were analyzed as follows: 
 
To the MALDI plate 0.75 ul of Alpha-cyano-4-hydroxycinnamic acid (α-CHCA) matrix (5  
 
mg/ml in 75% acetonitrile/ 0.1% TFA) and 0.75 ul of protein digest was added, mixed on the  
 
plate and air-dried under a gentle stream of warm air. The MALDI plates had previously been  
 
optimized for mass accuracy with the OptiPlate software in the Voyager 5.1 software (Applied  
 
Biosystems). PMF analysis of the digested proteins was done in the Automatic Control Mode  
 
with recalibrations every 4 samples using a mixture of Angiotensin 1 (M+H 1296.6853),  
 
ACTH 1-17 (M+H 2093.0867), and ACTH 18-39 (M+H 2465.1989), and when present, the  
 
spectra were internally calibrated with the autolytic fragment from trypsin (MH+ 842.5100 m/  
 
z). 200 laser shots were averaged, and then smoothed, background corrected and converted  
 
to the monoisotopic values with Data Explorer (Applied Biosystems) The resulting peak lists  
 
were submitted to MASCOT for database searching. 
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5.2 In Vitro Oxidation of Ferritin and Transferrin Experiments 
 
Horse Spleen Ferritin and Human serum Transferrin were purchased from Sigma and, in  
 
eight separate microcentrifuge tubes (Eppendorfs) they were treated, according to the  
 
method of Rudek et al. (2000) with two different concentrations of 50 uL hydrogen peroxide  
 
(10 and 20 uM) in 250 uL of 20 mM phosphate buffer pH 7.2. The tubes were incubated in a 
 
water bath at 37ºC as shown in Table 2. 
 
 
Table 2:  The different concentrations of H2O2 and the time of exposure of ferritin and 
 
transferrin to oxidative stress 
 
 
Protein 
 
 
H2O2 Concentration 
 
 
Time of Exposure 
 
 
 
Ferritin       no.   1   
 
                   no.  2                          
 
                   no.  3                          
 
                   no.  4                          
 
Transferrin no.   1   
 
                   no.   2 
                    
                   no.   3 
                    
                   no.   4                         
                    
 
 10 µM 
 
 10 µM                                         
 
 20 µM 
   
 20 µM 
 
 10 µM 
 
  10 µM 
 
  20 µM 
 
  20 µM                                      
 
 ½ hour 
 
 3  hours 
 
 ½ hour 
 
 3  hours 
 
 ½ hour 
 
 3 hours 
 
 ½ hour 
 
 3 hours 
 
 
 
500 µL of 10 mM EDTA (iron chelator) was added to each Eppendorf  tube and the reaction  
 
tubes were transferred to ice. According the method of Conrad et al. (2000) with some 
 
modifications, the reactants were removed by dialysis for 16 hours at 4ºC against at least 
 
125,000 volumes of 20 mM Tris/150 mM NaCl, pH 6.8. The first cycle of dialysis contained 
 
10 mM EDTA.  
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The samples were then subjected to proteolytic digestion using trypsin, for subsequent  
 
protein identification or characterization. 
 
5.2.1 Poroszyme method for Protein Digestion 
 
The protocol used for (immobilized trypsin bead) digestion of ferritin and transferrin  
 
standards, as described in Section 5.1.1, was also applied to the in vivo experiments. 
 
5.2.2 Protein Identification by Q-TOF LC-MS/MS 
 
The digest was evaporated to dryness, then dissolved in 12 µl of 1% aqueous TFA, of which  
 
6 µL were analyzed by LC-MS/MS using a capLC ternary HPLC system (Waters, Milford, MA, 
 
USA) interfaced to a Q-TOF Ultima Global hybrid tandem mass spectrometer fitted with a Z- 
 
spray nanoelectrospray ion source (Micromass, Manchester, UK). Solvent A and C were  
 
comprised of 0.2% formic acid in water, while solvent B consisted of 0.2% formic acid in  
 
acetonitrile. The peptide digest sample was loaded onto a C18 trapping column  
 
(Symmetry 300, 0.35 x 5 mm Opti-pak; Waters) and washed for 3 min using solvent C at a  
 
flow rate of 30 μL/min. The flow path was then switched using a 10-port rotary valve, and the  
 
sample eluted onto a C18 analytical column (PepMap, 75 μm x 15 cm, 3-μm particle size; LC  
 
Packings). Separations were performed using a linear gradient of 5:95% to 60:40 % B: A  
 
period of 43 min. The composition was then changed to 80:20 % B: A and held for 10 min to  
 
flush the column before re-equilibrating for 7 min at 0:100 % A: B. Mass calibration of the Q- 
 
TOF instrument was performed using a product ion spectrum of Glu-fibrinopeptide B acquired  
 
over the m/z range 50 to 1900. LC-MS/MS analysis was carried out using data dependent  
 
acquisition, during which peptide precursor ions were detected by scanning from m/z 400 to  
 
1900 in TOFMS mode. Multiply charged (2+, 3+, or 4+) ions rising above predetermined  
 
threshold intensity levels were automatically selected for TOF-MS/MS analysis, by directing  
 
these ions into the collision cell where they were fragmented using low energy CID by 
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collision with argon. Product ion spectra were acquired over the m/z range 50-900. LC- 
 
MS/MS data were processed using de novo sequencing software package PEAKS to assign  
 
as many high abundance peaks in the spectrum as possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                                                    
 
                                                                              
 
43 
 
5.3 In Vitro Excess Iron Overload and Oxidation of Ferritin 
 
These experiments were conducted according to the methods of Silva, D.et al. 1992; Conrad,  
 
C. et al. 2000, and Davies et al. 2003, with some modifications: 
 
- 10 µL of Horse Spleen Ferritin (Sigma) were incubated in 700 uL of HEPES buffer pH 
 
      7.0 (8 preparations). 
 
- 4 of these preparations were treated with 50 µL of 10 uM hydrogen peroxide, the other 
 
     4 were treated with 50 uL of 20 uM hydrogen peroxide. 
 
- All preparations were incubated in a water bath at 37ºC for 3 hours. 
 
- 50 µL of 0.5 mM ferrous ammonium sulfate was added to 4 preparations (2 with low 
 
      hydrogen peroxide concentration and the other 2 had high hydrogen peroxide 
 
      concentration). 
 
- 200 µL of 0.5 mM ferrous ammonium sulfate was added to the other 4 preparations 
 
      (2 with low hydrogen peroxide concentration and the other 2 with the higher hydrogen 
 
      peroxide concentration). 
 
- The 0.5 mM ferrous ammonium sulfate was added 10 times at 37ºC with 3 min interval  
 
      for half hour. 
 
- 4 out of those preparations underwent thermal denaturation by heating at 95ºC for 7 
 
      minutes followed by quick chilling on ice. However the other 4 did not undergo thermal 
 
      denaturation. 
 
- Reactants were removed by overnight dialysis at 4ºC against at least 125,000 volumes 
 
      of 20 mM Tris/150 mM NaCl, pH 6.8. 
 
- Samples were collected the next day and washed twice using 100 mM ammonium 
 
      bicarbonate. 
 
- The samples were analyzed by Q-TOF LC-MS/MS. 
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5.4 In Vitro Excess Iron Overload and Oxidation of Transferrin 
 
5.4.1 Experimental Design 
 
       These experiments were conducted according to the methods of Chahine, JM. et al.,  
 
       1996, 1999 and Davies, J. et al. 2003, with some modifications: 
 
- 8 preparations were prepared by incubating 10 µl of serum transferrin in ~ 300 ul of 20 
 
      mM sodium bicarbonate for each. 
 
- 4 out of these preparations were allowed to interact with only one equivalent of FNAc3,  
 
      the other 4 were allowed to interact with 2 equivalents of FNAc3. The reaction mix  
 
      was incubated for 4 hours 37ºC in a water bath. 
 
- Half of the preparations were treated with 50 uL of 10 µM hydrogen peroxide, the other 
 
      half was treated with 50 ul of 20 uM hydrogen peroxide. 
 
- Half of the preparations were heated at 95ºC for 7 minutes, followed by quick chilling  
 
      on ice for denaturation. The other half was not heated. 
 
- Reactants were removed by dialysis for 16 hours at 4ºC against at least 125,000  
 
      volumes of 20 mM Tris/150 mM NaCl, pH 6.8. 
 
- The samples were washed with ~ 250 µL of 100 uM ammonium bicarbonate after 
 
removal from the dialysis membranes. 
 
- The proteins were digested into peptides and analyzed by Q-TOF LC-MS/MS using  
 
           the same protocol mentioned above on page 41. 
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5.5 In Vivo Detection of Oxidative Modification in Plasma Samples of  
 
       Patients of Hereditary Hemochromatosis (HH) 
 
We used the methods of Michielsen, E. et al, 2005 Sisson, T. et al. 1990, a highly sensitive 
 
immunoprecipitation technique for extracting and concentrating proteins such as ferritin and 
 
transferrin in the plasma samples from patients with HH with a few modifications. 
 
 5.5.1 Immunoprecipitation Protocol 
 
• The reactions were performed at room temperature. 
 
• 100 mg of protein-G agarose (Sigma) was washed once with phosphate-buffered 
 
       saline (PBS), pH 7.0 and then blocked with 250 µL of 1 g/L bovine serum albumin 
 
       (BSA) (Sigma) in PBS for 60 min. 
 
• A mixture of anti-ferritin and anti-transferrin antibodies (Sigma) [2 µL of each of a 
 
      concentration of 55 µg of each antibody]. This mixture was mixed with PBS containing 
 
      1g/L BSA. 
 
• Upon thorough mixing, the mixture was mixed with agarose beads and rotated for 1 h. 
 
• After binding the antibodies, the beads were washed twice with excessive PBS. 
 
• Antibodies were cross-linked to protein G-agarose by the addition of 200 mM  
 
      triethanolamine (Pharmacia Biotech) in PBS to which 50 mM dimethyl pimelimidate 
 
      (Sigma) was added directly before use (final pH 8.6) with rotation for 30 min. 
 
• Cross-linking and washing were repeated twice to improve cross-linking efficiency. 
 
• To each eppendorf, 250 µL of plasma, 100 µL of 6 M urea and 150 µL PBST (PBS 
 
      containing 0.2 mL/L Tween 20) and protein G-agarose beads were added, then  
 
      rotated for 90 min and washed twice with PBST. 
 
• Elution was performed by heating at 56ºC for 20 min in 100 µL of 1 M glycine, pH 3.0. 
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• Samples were centrifuged and supernatants were kept for analysis. 
 
• Samples for electrophoresis were prepared by adding 20 µL of sample buffer (40 mM 
 
      tris/HCl, 33 g/L SDS, 500 ml/L glycerol and Bromophenol Blue) to 50 µL of the eluate. 
 
  5.5.2 SDS-Polyacrelamide Gel Electrophoresis (Linear Slab Gel) 
  
  A rapid method was used for qualifying, comparing and characterizing proteins which  
 
  separates proteins based primarily on their molecular weights as described by Laemmli, 
 
  1970. 
 
• According to manufacturer’s (e.g. Rad Mini-Gel). The bottom of both gel plate  
 
     and spacer were perfectly flushed against a flat surface before tightening the  
 
     clamp assembly to avoid any leak. 
 
• 10% separating gel was prepared by adding 4.1 mL distilled water, 2.5 mL of  
 
                      1.5 M Tris-HCl (pH 8.8), 3.3 mL of acrylamide/bis-acrylamide, 50 μL of 20%  
 
                      SDS and 50 μL of 10% ammonium persulfate. 15 μL of TEMED was added  
 
                     right before pouring the separating gel solution onto the gel sandwich using a  
 
                     pipette. 
 
• About 15 min were allowed for polymerization. 
 
• 4% stacking gel was prepared; 3.075 mL distilled water, 1.25 mL of 0.5 M Tris- 
 
      HCl pH 6.8, 25 μL of 20% SDS, 0.67 mL of 30% acrylamide/bis-acrylamide,  
 
      and 25 μL of 10% ammonium persulfate.  10 μL of TEMED was added right  
 
      before pouring the stacking gel solution onto the gel sandwich. 
 
• The stacking gel was added onto the gel sandwich until the solution reached  
 
      the top of the front plate. 
 
• A comb was carefully inserted into the gel sandwich until the bottom of the  
 
      teeth reached the top of the front plate. 
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• About 30 min were allowed  for the stacking gel to polymerize , followed by  
 
      careful removal of the comb. 
 
• Using a Hamilton syringe, 30 μL of the sample solution was introduced into the  
  
      wells, avoiding air bubbles and leaving reasonable spaces among wells. 
 
• Within the Mini-Protean electrophoresis chamber , the gel was placed and a  
 
      running buffer was added to the inner and outer reservoirs. 
 
NOTE: To prepare 1 liter of running buffer pH 8.3, 15 g of Tris Base was added to  
 
            72 g Glycine and 5 g SDS in distilled water to a final volume of 1 liter. 
 
• A molecular mass standard was run in parallel. 
 
• The gel was run at 120 V for approximately 40-50 min using a Power-Pac 300  
 
      power supply (Biorad). 
 
• After turning the power off,  the electrodes as well as the spacer and the gel  
 
      plate were removed.  
 
• The gel was completely soaked in Coomassie Blue Stain for 10-20 min. 
 
• About 50 mL of Coomassie destain was added overnight after pouring the stain  
 
     out. 
 
• The appropriate bands were excised the following day for digestion by  
 
      proteolytic enzymes (Trypsin). 
     
5.5.3 Trypsin Digestion 
 
• Coommasie de-stain: 
 
            Samples were dispensed with 50 µL of 100 µM ammonium bicarbonate and 50 µL 
 
            acetonitrile, followed by a10 min incubation at room temperature. 150 µL from each  
 
            well was aspirated. Another 50 µL of ammonium bicarbonate and acetonitrile were  
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            added followed by another 10 min incubation. 95 µL from each well were aspirated. 
 
• Dehydration: 
 
      Samples were treated with 50 µL acetonitrile, and allowed to stand for 5 min. 45 µL  
 
            were aspirated and followed by 15 min incubation. 
 
• Reduction: 
 
            50 µL 10 mM Dithiothreitol (DTT) were added and allowed to stand for 30 min. 
 
• Alkylation: 
 
50 µL 55 mM iodoacetamide was added and allowed to stand for 20 min. Another 100 
 
            µL acetonitrile was added and allowed to stand for 5 min waiting. 195 µL were  
 
            aspirated from each well. 
 
•  Wash: 
 
  50 µL ammonium bicarbonate was added twice, followed by 10 min and 5 min 
 
             incubation. 120 µL were aspirated.  
       
• Dehydration I: 
 
 50 µL acetontrile was dispensed followed by 5 min waiting. 45 µL were aspirated from 
 
            each well. 
 
• Dehydration II: 
 
50 µL acetonitrile was added, followed by 5 min incubation. 75 µL from each well were 
 
            aspirated followed by another 5 min incubation. Heater tiles were switched off and 
 
            allowed to stand for 30 min. 
 
• Preparation of Trypsin: 
 
            Water as well as 100 mM ammonium bicarbonate were dispensed to each trypsin 
 
            vial with mixed aspiration and dispensation. Final concentration of trypsin was 6  
 
            ng/µL. 
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• Digestion: 
 
25 µL trypsin was added, followed by 30 min incubation. Heater tiles were switched  
 
            on and allowed to stand for about 4.5 hours. Heater tiles were switched off. 
 
• Extraction I: 
 
            30 µL of 1% formic acid and 2% acetonitrile solution were dispensed, followed by 30  
 
            min incubation. 
 
• Peptide Transfer: 
 
           15 µL were aspirated from each well and dispensed to cooled PCR plate. 
 
• Extraction II: 
 
12 µL formic acid and 12 µL acetonitrile solution were dispensed, followed by 30 min 
 
            incubation. 15 µL were aspirated from each well and dispensed to cooled microtiter  
 
            plate. 
 
• Extraction III: 
 
Same as extraction II. 
 
            Note:  Fixed tips were used for all reagent conditions: 
 
              -  200 µL MBP tips were used for all aspirations to waste. Used 200 µL MBP tips 
 
                  were discarded. 
 
              -  20 µL MBP tips were used for peptide transfer. Used ones were discarded. 
 
5.5.4 Analysis using MALDI-TOF and Q-TOF LC-MS/MS  
 
        The same protocol mentioned above on pages 37 and 40 was used. 
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5.6 Specrophotometric Assay for the Detection of Protein Carbonyls in the  
 
      Plasma Samples of Patients With Hereditary Hemochromatosis  
 
The methods used were those of Levine, R. et al. 1990, 1994; Reznick, A. et al. 1994 and 
 
Shacter, E. 2000. The most convenient procedure to detect and quantitate the carbonyl  
 
content in protein preparation is the reaction with 2,4-dinitrophenylhydrazine (DNPH). DNPH 
 
reacts with protein carbonyls, forming a Schiff base to produce the corresponding hydrazone, 
 
which can be analyzed spectrophotometrically at a wavelength of 370 nm. 
 
 5.6.1 Assay Range 
 
This assay works best when the samples have protein concentration in the range of 1.0-10  
 
mg/mL. 
 
 5.6.2 Pre-Assay Preparation and Stock Solutions 
 
1. Hydrochloric acid: 2.5 M HCl was prepared to resuspend the DNPH.  
 
2. 2,4-dinitrophenylhydrazine (DNPH): 10 mM was resuspended in 2.5 M HCl. DNPH  
 
            is stable for one week at 4°C in the dark. 
 
3. Trichloroacetic Acid Solutions (TCA): 10% and 20% solutions were prepared for  
 
           the precipitation of the plasma proteins. Both solutions are stable at room  
 
           temperature for at least one week. 
 
4. Guanidine Hydrochloride: 6 M of Guanidine HCl were prepared for redissolving of  
 
           the protein. 
 
5. Ethanol/Ethyl Acetate: 1:1 ethanol / ethyl acetate were prepared to help remove  
 
           the free reagents from the protein preparations. 
 
  5.6.3 Plasma Samples Preparation 
 
  A 5.0 mL blood sample was collected from each untreated HH patient as well as one  
 
  normal individual as a control, in heparinized tubes. Six patients who gave consent were 
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  recruited from HH patients attending the Department of Internal Medicine (Gastroenterology 
 
  and Hepatology Division) at the Royal University Hospital in Saskatoon, Saskatchewan,  
 
  Canada. The blood samples were centrifuged upon withdraw at 2000-x g for about 15 min 
 
  to collect plasma which was stored on ice until use or frozen at -20ºC. 
 
 
Table 3: Comparison of Control and HH patients. ND*: Not determined, Sex*: Males 
 
are predominant. 
             
 Control  Patient 
1 
Patient 
2 
Patient 3 Patient 4 Patient 5 Patient 6 
Age 44 49 41 41 40 63 56 
Sex* M F M M M M F 
Serum 
ferritin, ng/ml 
(N: 20 –250) 
 
55 
 
182 
 
1517 
 
195 
 
767 
 
870            
 
310 
Serum 
transferrin 
saturation, % 
(N: 17 – 50) 
 
22 
 
54 
 
93 
 
ND* 
 
82 
 
76 
 
78 
Serum iron, 
µM/L (N: 11.6 
– 31.3) 
 
ND 
 
25 
 
52 
 
ND 
 
36 
 
39 
 
ND 
AST, U/L (N: 
8 – 20) 
10 24 114 49 22 38  
ND 
ALT, U/L (N: 
8 – 20) 
12 30 158 59 36 51 ND 
Clinical 
information 
ND Two 
copies 
of 
C282Y 
& 
Fatigue 
One 
copy of 
H63D 
& HCV 
positive
C282Y/
H63D 
compou
nd 
heteroz
ygote 
Two 
copies 
of 
C282Y 
& fatty 
liver 
C282Y/
H63D 
compou
nd & 
fatty 
liver. 
ND 
 
 
5.6.4 Procedure 
 
• 100 µL of each sample (including the control) was transferred to 2.0 mL plastic tubes. 
 
• 400 µL of DNPH was added to sample tubes, while 400 µL of 2.5 M HCl were added  
 
      to the control. 
 
• All tubes were incubated in the dark at room temperature for one hour with vortexing 
 
      each tube every 15 min during the incubation. 
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• 0.5 mL of 20% TCA was added to each tube. Tubes were incubated on ice for 5 min. 
 
• Tubes were centrifuged at 10,000-x g for 10 min. 
 
• The supernatants were discarded and the pellets were resuspended in 0.5 mL of 10%  
 
TCA, and reincubated  incubated on ice for 5 min. 
 
• Tubes were centrifuged at 10,000-x g for 10 min. 
 
• The supernatants were discarded and the pellets were resuspended in 0.5 mL of (1:1)   
 
      ethanol/ethyl acetate with thorough vortexing and centrifugation at 10,000 x g for 10  
 
      min. 
 
• Last step was repeated twice. 
 
• After the final wash, protein pellets were resuspended in 0.5 mL of guanidine HCl and 
 
      heated for 15 min at 37°C. 
 
• Tubes were centrifuged at 10,000 x g for 10 min to remove the insoluble materials. 
 
• The UV/Visible Spectrophotometer (Pharmacia Biotech) was used to obtain the  
 
      spectrum by reading samples against 2.5 M HCl as a blank. 
 
• The carbonyl content was measured from the maximum absorbance (370 nm) using a 
 
      molar absorption coefficient of 22,000 M ⎯¹ cm ⎯¹. 
 
 5.6.5 Determination of Carbonyl Content 
 
• The average absorbance of each sample and control were calculated. 
 
• The average absorbance of the control was subtracted from the average absorbance 
 
      of the samples to give the Corrected Absorbance (CA). 
 
• The concentrations of the carbonyls were determined by inserting the CA into the  
 
      following equation: 
 
Protein Carbonyl (nmol/ml) = [(CA)/(22,000 M ⎯ ¹cm⎯ ¹)](500 µL/200µL) 
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6.0 Results 
     
6.1 Results from 'gel-free' protein digest experiments 
 
Transferrin digest provided enough tryptic peptides, and in sufficient quantities, to easily 
  
identify the protein by peptide mass fingerprinting using MALDI-TOF MS as shown in Fig.5 
 
(A). Analysis of modified (and unmodified) peptides from endogenous levels of transferrin 
 
should therefore be straightforward using the Q-TOF instrument for LC-MS/MS analysis 
 
(which is required to identify and locate modifications due to oxidation). 
 
Ferritin was not identified by peptide mass fingerprinting from amount of material used, 
 
although the MALDI-TOF spectrum shown in Fig.5 (B) did contain one or two weak ions that 
 
might have corresponded to tryptic peptides. 
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(A) Transferrin 
 
MALDI-TOF MS spectrum of immobilized trypsin digest 
 
 
 
 
 
 
MASCOT search result (SwissProt database)  
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(B) Ferritin 
 
MALDI-TOF MS spectrum of immobilized trypsin digest 
 
 
 
 
 
 
  
MASCOT search result (SwissProt database) 
 
 
 
 
 
 
Fig.5: MALDI-TOF MS spectra of immobilized trypsin (Poroszyme) digests and MASCOT  
 
peptide mass fingerprint (PMF) using SwissProt databases for (A) Transferrin (6 μg) and  
 
(B) Ferritin (60 ng). 
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6.2 Oxidized and unmodified peptides matching human transferrin and 
 
       ferritin 
      
Data were acquired by Q-TOF LC-MS/MS analysis of immobilized trypsin digests of proteins 
 
oxidized in vitro. 
 
Database searches were performed using PEAKS software and the following modifications: 
 
- oxidation of M, H, or W by a single oxygen atom (OxM, OxH, OxW) 
 
- oxidation of M, H, or W by two oxygen atoms (OOM, OOH, OOW) 
 
- oxidation of W to Kynurenine (KyW) 
 
- oxidation of W to 3-hydroxy Kynurenine (OHKyW) 
 
 Oxidized peptides that give a significant match with human transferrin or ferritin are  
 
 highlighted in red, may be used for targeted LC-MS/MS analysis in future experiments  
 
 involving animal and human tissue and plasma samples. 
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6.2.1 Transferrin 
 
6.2.1.1 Oxidized peptides that provided significant matches (≥50 %) with human transferrin (i.e.  
 
            targets for LC-MS/MS analysis) 
 
Table 4 shows oxidized and unmodified peptides matching human transferrin showing  
 
different m/z,charge, mr (calc) and score for different peptides. 
 
Transferrin Sample 003 
 
gi|6980467   more... Chain A, Human Transferrin N-Lobe Mutant H249e 
 
 Mass: 36789.996   Score: 95.89% Coverage: 44.91% 
 
Mz Charge Mr (calc) Start End Score Peptide 
489.731 2 959.4712 197 206 60.78% DGAGDVAFVK 
489.778 2 959.4712 197 206 8.96% DGAGDVAFVK 
489.7922 2 959.4712 197 206 37.95% DGAGDVAFVK 
544.8204 4 2157.016 236 254 20.25% DEYKDC(OxH)LAQVPSETVVAR 
544.8688 4 2157.016 236 254 1.18% DEYKDC(OxH)LAQVPSETVVAR 
    568.651 4 2252.1226 258 276 1.09% GKEDLIWELLNQAQE(OxH)FGK 
580.0648 4 2298.128 260 278 6.76% EDLI(KyW)ELLNQAQEHFGKDK 
625.6363 3 1855.8853 264 278 2.48% (OOW)ELLNQAQEHFGKDK 
680.1284 4 2699.3125 254 276 3.86% RS(OxM)GGKEDLI(OxW)ELLNQAQEHFGK 
698.1269 4 2770.3384 255 278 82.78% S(OxM)GGKEDLIWELLNQAQEHFGKDK 
740.8903 4 2942.4343 254 278 2.64% RS(OxM)GGKEDLI(OxW)ELLNQAQEHFGKDK 
747.8765 2 1475.7119 313 324 99% (OxM)YLGYEYVTAIR 
755.1469 4 2997.4766 253 278 1.33% ARSMGGKEDLIWELLNQAQE(OxH)FGKDK 
762.4193 3 2267.152 124 143 1.3% RSAG(OxW)NIPIGLLYCDLPEPR 
762.4345 3 2267.152 124 143 72.46% RSAG(OxW)NIPIGLLYCDLPEPR 
781.4538 3 2324.1736 123 143 20.63% GRSAG(OxW)NIPIGLLYCDLPEPR 
799.1362 4 3174.5515 206 232 50.38% KHSTIFENLANKADRDNYELLCLDNTR 
827.6469 4 3289.615 205 232 46.02% VK(OxH)STIFENLANKADRDNYELLCLDNTR 
989.3256 4 3934.9993 51 88 99% AIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSK 
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1065.1929 3 3174.5515 206 232 1.17% KHSTIFENLANKADRDNYELLCLDNTR 
1318.7422 3 3934.9993 51 88 17.6% AIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSK  
 
 
 
 
Table 4 shows a significant high score of oxidized Met and Trp, 82.8% 99% and 72%  
 
respectively as highlighted in red. The m/z column indicates the mass to charge ratio, while  
 
the mr(calc) column indicates the corresponding total mass of the amino acid residues in the 
 
detected peptide. The start column indicates the first amino acid residue of the peptide  
 
matching while the end column indicates the last amino acid residue of the matching peptide. 
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6.2.2 Ferritin 
 
6.2.2.1 Oxidized peptides that provided significant matches (≥ 50 %) with horse spleen ferritin  
 
            (i.e.targets for LC-MS/MS analysis)                                              
 
Table 5 shows oxidized and unmodified peptides matching horse spleen ferritin showing 
 
different mz, charge, mr (calc) and score for different peptides. 
 
Mass: 19814.104   Score: 100% Coverage: 50.57%  
Mz Charge Mr(calc) Start End Score Peptide 
437.7761 2 855.445 53 59 60.33% ELAEEKR 
445.7761 2 871.52795 19 25 99% LVNLYLR 
445.8241 2 871.52795 19 25 92.13% LVNLYLR 
481.8107 2 943.5127 76 83 35.45% ALFQDLQK 
494.2751 3 1461.6848 6 18 97.22% QNYSTEVEAAVNR 
538.3058 2 1056.52 9 18 99% STEVEAAVNR 
547.0021 3 1619.8307 154 168 99% LVGSQAGLGEYLFER 
584.0082 3 1730.87 4 18 73.18% IRQNYSTEVEAAVNR 
619.8489 2 1219.5833 8 18 99% YSTEVEAAVNR 
676.8781 2 1333.6262 7 18 56.02% NYSTEVEAAVNR 
713.9045 2 1407.6782 156 168 95.04% GSQAGLGEYLFER 
740.8243 2 1461.6848 6 18 99% QNYSTEVEAAVNR 
740.9094 2 1461.6848 6 18 99% QNYSTEVEAAVNR 
763.4441 2 1506.7466 155 168 86.25% VGSQAGLGEYLFER 
784.8048 3 2333.2126 6 25 95.91% QNYSTEVEAAVNRLVNLYLR 
819.9608 2 1619.8307 154 168 99% LVGSQAGLGEYLFER 
819.9691 2 1619.8307 154 168 93.72% LVGSQAGLGEYLFER 
819.9781 2 1619.8307 154 168 94.67% LVGSQAGLGEYLFER 
819.9949 2 1619.8307 154 168 99% LVGSQAGLGEYLFER 
   819.995 2 1619.8307 154 168 98.9% LVGSQAGLGEYLFER 
819.9955 2 1619.8307 154 168 98.26% LVGSQAGLGEYLFER 
  
 
                                                                    
 
                                                                              
 
60 
 
819.9958 2 1619.8307 154 168 99% LVGSQAGLGEYLFER 
819.9989 2 1619.8307 154 168 95.8% LVGSQAGLGEYLFER 
820.0275 2 1619.8307 154 168 84.08% LVGSQAGLGEYLFER 
846.7948 3 2519.2002 76 97 81.05% ALFQDLQKPSQDEWGTTLDA(OxM)K 
855.2383 4 3399.7495 75 104 22.31% RALFQDLQKPSQDEWGTTLDA(OxM)KAAIVLEK 
860.4593 3 2560.2842 82 104 4.13% QKPSQDE(OHKyW)GTTLDAMKAAIVLEK 
865.797 3 2576.279 82 104 5.29% QKPSQDE(OHKyW)GTTLDA(OxM)KAAIVLEK 
912.8155 3 2717.3582 81 104 1.51% LQKPSQDE(OOW)GTTLDA(OOM)KAAIVLEK 
936.4847 3 2788.3953 80 104 2.2% DLQKPSQDE(OHKyW)GTTLDAMKAAIVLEK 
 
 
Table 5 shows a significant score (81.05%) for oxidized Met at a single O atom, as  
 
highlighted in red. This table also indicates that the doubly, triply and the quadruply charged  
 
ions shown in the m/z column are 18 Daltons larger than those shown in the Mr (calc) when  
 
the m/z is multiplied by the number of the charges. This is because PEAKS does not account  
 
for the absence of  H2O (H+ at C- terminal and OH¯ at N-terminal) when using the masses of  
 
the component amino acid residues to determine Mr(calc). 
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6.2.3 Oxidized peptides that provided significant matches with human  
 
          transferrin (i.e. targets for LC-MS/MS analysis) 
  
Table 6 Summary of the significant matches with human transferrin including only the  
 
              oxidized peptides from all samples. 
 
606.3192 2 1192.5295 123 132 73.24% DSGFQ(OxM)NQLR 
666.6204 4 2645.3496 251 273 71.4% RKPVDEYKDC(OxH)LAQVPSHTVVAR 
698.1269 4 2770.3384 255 278 82.78% S(OxM)GGKEDLIWELLNQAQEHFGKDK 
747.8765 2 1475.7119 313 324 99% (OxM)YLGYEYVTAIR 
797.4498 2 1574.7915 476 489 92.85% TAGWNIP(OxM)GLLYNK 
762.4345 3 2267.152 124 143 72.46% RSAG(OxW)NIPIGLLYCDLPEPR 
846.7921 3 2519.2002 76 97 85.79% ALFQDLQKPSQDEWGTTLDA(OxM)K 
 
Note: most of the high scoring peptides are oxidized by attachment of a single O at  
 
          Methionine. 
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Figure 6 shows the annotated MS/MS of m/z 606.3192 in vitro sample MOH070505_002.  
 
Strong y-type ions are shown (y, y2, y4, y6 and y7) and x9. Both x and y-type ions retain  
 
the C-terminal residues. x-type ion is only formed predominantly in high energy dissociation  
 
experiments at C-terminal. Only one a-type ion (a2-type) is shown that retains the N-terminal  
 
residue. The abundance of y-type ions is typical of low energy CID experiments. 
 
 
 
 
 
 
 
 
Fig.6:  MS/MS spectrum of m/z 606.3192 from in vitro sample MOH070505_002, 
 
            annotated by PEAKS after database matching against transferrin (Accession 
 
gi|31415705; 73.2% confidence). 
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6.2.4 Oxidized peptides that provided significant matches with horse  
  
         spleen ferritin (i.e. targets for LC-MS/MS analysis) 
 
Table 7 Summary of oxidized peptides that provided significant matches with horse  
 
             spleen ferritin including only the oxidized peptides from all samples. 
 
 
846.7972 3 2519.2002 76 97 89.77% ALFQDLQKPSQDEWGTTLDA(OxM)K 
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6.3 Database search results for ferritin and transferrin LC-MS/MS data  
 
        processed using PEAKS 
 
As described in Materials and Methods Section; oxidative stress and excess iron load were 
 
induced in both horse spleen ferritin and human serum transferrin.     
 
KEY: (OxM) = methionine oxidized with one O 
 
 (OOM) = methionine oxidized with two O 
 
 (OxH) = histidine oxidized with one O 
 
 (OOH) = histidine oxidized with two O 
 
 (OxW) = tryptophan oxidized with one O 
 
 (OOW) = tryptophan oxidized with two O 
 
N.B. – this list shows only the oxidized tryptic peptides that matched ferritin or transferrin.  
 
The same peptide sequence may appear more than once in each sample, either because 
 
it was detected as two peptide ions of different charge, or because two or more versions of 
 
that peptide containing different modifications were matched. 
 
Oxidized peptides that match with reasonable confidence (i.e. Score = 50% or better) are 
 
highlighted in red. 
 
Oxidized peptides that have a relatively low score (< 50%) are marked in blue, and should be 
 
disregarded unless they are detected in more than one sample. 
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 6.3.1 Ferritin 
 
 6.3.1.1 Native Ferritin with 20 μM H2O2 
 
Table 8 shows different mz, charges, mr (calc) and scores for different peptides of native 
 
ferritin oxidized with 20 uM H2O2. OxM shows a significant confidence score of 52.47-79.4% 
 
at a single O as highlighted in red. However, relatively low scoring (OxM and OOH), 
 
highlighted in blue, are also shown. 
 
Mass: 19844.473   Score: 88.03% Coverage: 33.33% 
Mz Charge Mr (calc) Start End Score Peptide 
400.9225 3 1199.5718 144 153 79.41% (OxM) GDHLTNIQR 
600.8906 2 1199.5718 144 153 52.47% (OxM) GDHLTNIQR 
616.8919 2 1231.5615 144 153 35.72% (OxM) GD(OOH)LTNIQR 
770.4661 2 1538.6824 40 52 7.31% DDVALEGVC(OOH)FFR 
 
6.3.1.2 Denatured Ferritin with 20 μM H2O2  
 
Table 9 shows different mz, charges, mr (calc) and scores for different peptides of 
 
denatured ferritin oxidized with 20 uM H2O2. OxH and OxM show a significant  
 
confidence score of 76.8% and 99% at a single O, as highlighted in red, respectively.  
 
A relatively non significant, low score (5.19%) of oxidized Met and His at 2 Os are also 
 
shown, as highlighted in blue. 
 
Mz Charge Mr (calc) Start End Score Peptide 
400.8713 3 1199.5718 144 153 76.83% MGD(OxH)LTNIQR 
846.7748 3 2537.2107 76 97 99% ALFQDLQKPSQDEWGTTLDA(OxM)K 
1117.5837 3 3349.745 140 168 5.19% LIKK(OOM)GD(OOH)LTNIQRLVGSQAGLGEYLFER 
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6.3.2 Transferrin 
 
6.3.2.1 Native Transferrin with 20 μM H2O2 
 
  Table10 shows different mz, charges, and score of different peptides of native transferrin 
 
oxidized with 20 uM H2O2. Confidence scores of oxidized Met, and Trp at a single O were 
 
detected with an average of 84.5 – 99 and 93.4 – 98.3%, as highlighted in red, respectively. 
 
Oxidized His is detected in this sample with a significant score of 81.6–91.4% only at (OOH)  
 
  i.e. no significant score for oxidized His at a single O (OxH) was detected. As well, no  
 
significant score for oxidized Met at 2 O s (OOM) was detected in this sample. Oxidized Trp 
  
  at 2 O s (OOW) is shown in one peptide with a score of 99%, as highlighted in red. As  
 
highlighted in blue, some low confidence scores (< 50%) were also detected at some other  
 
   locations. 
 
   Mass: 77079.92   Score: 99.88% Coverage: 36.39% 
 
Mz Charge Mr (calc) Start End Score Peptide 
453.7552 2 905.42426 316 323 87.58% DSA(OOH)GFLK 
498.7909 2 995.51483 601 609 91.42% APN(OOH)AVVTR 
526.9611 3 1577.8049 453 466 20.4% KSASDLT(OxW)DNLKGK 
584.2852 2 1166.4961 38 46 14.11% CQSFRDH(OxM)K 
633.3508 2 1264.5935 454 464 93.41% SASDLT(OxW)DNLK 
641.3419 2 1280.5884 454 464 99% SASDLT(OOW)DNLK 
642.3898 3 1923.9729 300 315 81.6% EFQLFSSP(OOH)GKDLLFK 
747.9221 2 1493.7224 332 343 99% (OxM)YLGYEYVTAIR 
797.3975 2 1592.802 476 489 84.5% TAGWNIP(OxM)GLLYNK 
805.4689 2 1608.7969 476 489 93.01% TAG(OxW)NIP(OxM)GLLYNK 
849.4998 3 2545.227 274 295 97.59% S(OxM)GGKEDLIWELLNQAQEHFGK 
1043.6183 2 2085.0166 279 295 98.33% EDLI(OxW)ELLNQAQEHFGK 
1051.6409 2 2101.0115 279 295 15.66% EDLIWELLNQAQE(OOH)FGK  
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Figure 7 shows the annotated MS/MS of m/z 747.9221in vitro samples DF-3. Strong y-type  
 
ions are shown (y4, y6, y7, y9 and y11). y-type ions retain the C-terminal residues. Only 
 
one a-type ion (a2-type), one b-type ion (b2) and one c-type ion (c2-type) are shown that 
 
retains the N- terminal residue. The peptide (OxM)YLGYEYVTAIR (m/z 747.9221) was found  
 
in virtually all the in vitro samples of oxidized transferrin, and was the peptide that best  
 
matched transferrin in the database searches (with 99%) confidence. This would be the best  
 
example of a peptide that demonstrates oxidation of transferrin in vitro.   
 
 
 
 
Fig.7:  MS/MS spectrum of m/z 747.9221 from in vitro sample DF-3, annotated by 
 
PEAKS after database matching against transferrin (Accession gi|62897069; 
 
              99% confidence). 
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Figure 8 shows the annotated MS/MS of m/z 797.5536 in vitro samples NT-4. y-type ions  
 
are shown (y2 , y3 ). y-type ions retain the C-terminal residues. No b-type ions were 
 
 annotated. 
 
 
 
 
 
 
 
 
Fig.8: MS/MS spectrum of m/z 797.5536 from in vitro  sample NT-4, annotated by 
 
PEAKS after database matching against transferrin (Accession gi|15021381; 
 
65.3% confidence). 
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6.3.2.2 Denatured transferrin with 20 μM H2O2 
 
Table 11 shows high significantly scores of oxidized Trp at both single and 2 O (s) with a  
 
score of 99%, as highlighted in red. A significant score of 83.6 – 98% is also shown for 
 
oxidized Met at a single O, as highlighted in red. A relatively non significant score of 5%  
 
was detected with oxidized His at both single and 2 O (s), as highlighted in blue. 
 
 
 
Mass: 77049.945   Score: 99.08% Coverage: 28.65% 
Mz Charge Mr(calc) Start End Score Peptide 
580.3556 2 1158.5928 133 143 5.32% GKKSC(OxH)TGLGR 
633.4001 2 1264.5935 454 464 99% SASDLT(OxW)DNLK 
641.3895 2 1280.5884 454 464 99% SASDLT(OOW)DNLK 
642.4209 3 1923.9729 300 315 53.05% EFQLFSSP(OOH)GKDLLFK 
747.9763 2 1493.7224 332 343 98.02% (OxM)YLGYEYVTAIR 
797.4877 2 1592.802 476 489 83.57% TAGWNIP(OxM)GLLYNK 
 993.5349 4 3969.9165 226 258 4.89% (OOH)STIFENLANKADRDQYELLCLDNTRKPVDEYK 
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Figure 9 shows the annotated MS/MS spectra of m/z 633.4001 from in vitro sample DT-4. 
 
Strong y-type ions are shown (y2, y3, y4 and y8). Only one b-type ion (b4-type) and one c- 
 
type ion (c4-type) are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: MS/MS spectrum of m/z 633.4001 from in vitro sample DT-4, annotated by 
 
PEAKS after database matching against transferrin (Accession gi|15021381; 
 
99% confidence). 
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Overall, The highest scoring was recorded for the samples exposed to both oxidative stress 
 
and iron incorporation. 
 
No significant differences were observed between native and denatured protein samples. 
 
Mapping of the oxidized residues onto the 3-D structure of Horse Spleen Ferritin showed   
 
them to be located on the inner face of each sub-unit, facing toward the ferritin core where 
 
iron is normally stored, as shown in Fig. 10, 11 and 12. Furthermore, methionine was  
 
oxidized to a greater extent than tryptophan or histidine yielding the highest scoring of  
 
modified peptides for both ferritin and transferrin in both in vivo and in vitro experiments. We  
 
suggest that the use of catalytic amounts of iron, rather low concentrations of hydrogen  
 
peroxide are sufficient to oxidize methionine. In the first portion of our in vitro work, we  
 
obtained an abundance of modified methionine residues in the presence of EDTA (iron  
 
chelator). In the second portion of our in vitro work, however, we obtained even higher  
 
scoring oxidatively modified methionine residues in the absence of EDTA. 
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Fig.10: 3-Dimentional structure of Horse Spleen Ferritin Molecule. Oxidized Met 
 
residues (yellow) are located on the inner face of each sub-unit. 
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Oxidized peptides matched in more than one transferrin sample (good  
 
candidates for targeted LC-MS/MS analysis): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11: 3-Dimentional structure of Horse Spleen Ferritin Molecule. Oxidized Trp 
 
residues (yellow) are located on the inner face of each sub-unit. 
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Fig.12: 3-Dimentional structure of Horse Spleen Ferritin Molecule. Oxidized His 
 
residues (yellow) are located on the inner face of each sub-unit. 
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6.4 Oxidized peptides identified during in vitro experiments and selected  
 
        for inclusion and targeted Q-TOF LC-MS/MS analysis of biological 
 
        samples 
   
 6.4.1 Transferrin 
 
Inclusion List (used for targeted LC-MS/MS analysis of HH patient samples) 
 
m/z  charge sequence 
 
430.2325 (2+)  NPDP(OOW)AK  
526.9611  (3+)  KSASDLT(OxW)DNLKGK 
532.0118  (3+)  TAGWNIP(OxM)GLLYNK 
544.8204  (4+)  DEYKDC(OxH)LAQVPSETVVAR 
599.8873  (2+)  (OOH)QTVPQNTGGK 
606.3192  (2+)  DSGFQ(OxM)NQLR 
633.3508  (2+)  SASDLT(OxW)DNLK    
641.3419  (2+)  SASDLT(OOW)DNLK 
642.3898  (3+)  EFQLFSSP(OOH)GKDLLFK 
666.6204  (4+)  RKPVDEYKDC(OxH)LAQVPSHTVVAR 
698.1269  (4+)  S(OxM)GGKEDLIWELLNQAQEHFGKDK 
747.9221  (2+)  (OxM)YLGYEYVTAIR 
762.4345  (3+)  RSAG(OxW)NIPIGLLYCDLPEPR 
781.4538  (3+)  GRSAG(OxW)NIPIGLLYCDLPEPR 
797.3975  (2+)  TAGWNIP(OxM)GLLYNK 
805.4689  (2+)  TAG(OxW)NIP(OxM)GLLYNK 
827.6469  (4+)  VK(OxH)STIFENLANKADRDNYELLCLDNTR  
846.7921  (3+)  ALFQDLQKPSQDEWGTTLDA(OxM)K 
855.2252  (4+)  RALFQDLQKPSQDE(OxW)GTTLDAMKAAIVLEK  
1043.6183  (2+)  EDLI(OxW)ELLNQAQEHFGK 
 
6.4.2 Ferritin 
 
Inclusion List (used for targeted LC-MS/MS analysis of HH patient samples) 
 
charge m/z                sequence 
 
400.9225  (3+)  (OxM)GDHLTNIQR 
560.306  (3+)  RDDVALEGVC(OxH)FFR 
600.8906  (2+)  (OxM)GDHLTNIQR  
616.8919  (2+)  (OxM)GD(OOH)LTNIQR 
846.7748  (3+)  ALFQDLQKPSQDEWGTTLDA(OxM)K 
855.2383  (4+)  RALFQDLQKPSQDEWGTTLDA(OxM)KAAIVLEK 
1111.9487  (3+)  LIKK(OOM)GD(OxH)LTNIQRLVGSQAGLGEYLFER 
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6.5 1-D SDS-PAGE for plasma samples of patients of HH 
 
As described earlier, immunoprecipitants of plasma samples from patients with HH were run  
 
on SDS-PAGE. A molecular weight marker (MWT) was run in parallel with the plasma  
 
samples, shown at right in Fig.13. This figure also shows the transferrin bands for the  
 
samples P4A, P2 and P2A from right to left, respectively. Transferrin bands were visualized  
 
by Commassie stain at the molecular mass of 78 kDa. The appropriately sized bands were  
 
then excised from the gel, destained and digested with a proteolytic enzyme (trypsin) to  
 
generate discrete peptide fragments for which molecular masses were determined. The  
 
protein digest was analyzed by Q-TOF LC-MS/MS, which confirmed the identity of transferrin  
 
and indicated the oxidative modifications of the amino acids methionine and tryptophan for  
 
samples P2 and P2A. Sample P4A did not show any oxidative modification for transferrin.  
 
This will be discussed in more detail later. 
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Fig.13: 1-D SDS-PAGE shows transferrin bands (Trf), visualized by Commasie stain at the 
 
molecular mass of 78 kDa from immunoprecipitants of plasma samples from patients with 
 
HH. The protein was loaded onto a 10% gel, stained by Commassie, 
 
destained and digested into peptide fragments by trypsin. 
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6.6 Summary of PEAKS database search results using data from targeted  
   
       LC-MS/ MS analysis of in previous in vitro experiments of oxidized 
 
       peptides 
          
Transferrin was identified in 4 of the 7 samples (P2, P2A, P4 and P6), either through  
 
matching of target oxidized peptides identified during the in vitro experiments, or matching of 
 
unmodified peptides whose m/z values were sufficiently close to those of the target oxidized 
 
peptides (in the inclusion list) to be selected for MS/MS (the other four samples matched only 
 
albumin or immunoglobulin). Results for samples P2, P2A, P4A and P6 showed transferrin as  
 
the top hit. Results for the other samples indicate that the top scoring proteins were neither 
 
transferrin nor ferritin,  which were not detected in these samples.  
 
Peptides highlighted in red are target peptides identified in in vitro experiments. Of the four  
 
samples in which transferrin was found, only two (P2 and P2A) matched to transferrin using  
 
target oxidized peptides identified in the earlier in vitro experiments. Conducting database  
 
searches allowed for identification of addition of O or OO to M, H or W  (as well as  
 
modification of W to kynurenine or 3-hydroxy-kynurenine) using the acquired peptide MS/MS 
 
spectra (i.e. those corresponding to the intended, target peptides in the inclusion list, or  
 
anything close enough in m/z to be selected for MS/MS). As a result, some peptides were 
 
matched to transferrin on the basis of one or more of these modifications, even though such 
 
peptides were not found in the in vitro experiments. However, the confidence with which  
 
 these individual peptides were matched to transferrin was low, while identification of 
 
 transferrin was based mainly on high-confidence matches from target (i.e. selected) oxidized 
 
 peptides and/or unmodified peptides that happened to be selected for MS/MS. 
 
 Consequently, only the three target oxidized peptides that matched transferrin were 
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 considered 'real', confirming one oxidized tryptophan and two oxidized methionine residues  
 
 in transferrin, as will be detailed later. 
 
6.6.1 Sample P2 
 
Table12 shows m/z, charges, and scores of different modified and unmodified peptides of  
 
protein digest of plasma Sample P2 of a patient with HH. 
 
Mass: 63407.215   Score: 27.27%  Coverage: 14.19%  
 
Mz Charge Mr(calc) Start End Score Peptide 
 
403.1744 3 1206.563 533 541 18.23% L(OOH)DRNTYEK 
544.9492 3 1631.8201 132 146 40.08% DCHLAQVPSHTVVAR 
633.15735 2 1264.5935 327 337 7.83% SASDLT(OxW)DNLK 
762.3158 2 1522.7415 171 183 4.57% SKEFQLFSSP(OOH)GK 
796.78906 2 1591.7156 389 403 2.83% LCMGSGLNLCEPNNK 
797.5013 2 1592.802 349 362 83.19% TAGWNIP(OxM)GLLYNK 
853.9678 2 1705.8999 326 340 2.45% KSASDLT(OxW)DNLKGKK
 
 
MS/MS analysis of the oxidatively modified peptide, SASDLT(OxW)DNLK (m/z 633. 15735) 
 
shows a score of 7.83% for OxW with a single O atom (See Fig.15). However, the analysis of  
 
the same sample for the oxidatively modified peptide, KSASDLT(OxW) DNLKGKK (m/z  
 
853.9678) revealed a score of 2.45% with a single O atom. 
 
MS/MS analysis of the same plasma sample for oxidatively modified peptide,  
 
TAGWNIP(OxM)GLLYNK, (m/z 797.5013) shows a significant score of 83.19% for OxM with  
 
a single O atom (See Fig. 14). 
 
MS/MS analysis of the oxidatively modified peptides, L(OOH)DRNTYEK (m/z 403.1744) 
 
and SKEFQLFSSP(OOH)GK (m/z 762.3158) show scores of 18.23% and 4.57% for OOH 
 
with two O atoms . 
 
Figure 14 shows the annotated MS/MS spectra of m/z (633.17535) from the in vivo sample in  
 
which two y-type ions are shown (y2, y3). y-type ions retain the C-terminal residues. Two z-  
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type ions (z2, z5-type) are also shown which retain the C-terminal residue as well. However  
 
z-type ions are weakly represented in this figure due to the fact that they only show  
 
abundance in high energy CID experiments. D(OxW)TLDSAS and LT(OxW)DNLK represent 
 
the theoretical partial sequences developed from C-terminal (y-type) and N-terminal (b-type) 
 
respectively. 
 
 
 
 
 
 
 
Fig.14: Annotated MS/MS spectrum for the peptide SASDLT(OxW)DNLK, m/z 
 
633.17535, showing singly charged y-type ion. b-type ion are not annotated 
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Figure 15 shows the annotated MS/MS spectra of m/z (797.5013) from the in vivo sample P2.  
 
four y-type ions are shown (y2, y3, y4, y5). One b-type ion (b3 -type) is also shown which   
 
retains the N-terminal residue. GI(OxM)PINWGAT and IP(OxM)GLLYNK represent  the 
 
theoretical sequences developed from C-terminal (y-type) and N-terminal (b-type) ions,  
 
respectively. 
 
 
 
 
 
 
Fig. 15: Annotated MS/MS spectrum for the peptide TAGWNIP(OxM)GLLYNK 
 
(m/z 797.5013) showing singly charged ion y3. 
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6.6.2 Sample P2A 
 
Table 13 shows m/z, charges, and scores of different modified and unmodified peptides of  
 
protein digest of plasma Sample P2A of a patient with HH. 
 
Mass: 131854.62   Score: 22.28%   Coverage: 5.12%  
 
Mz Charge Mr(calc) Start End Score Peptide 
531.30615 2 1060.5164 1197 1205 17.12% VFGWPQCPK 
544.98987 3 1631.8201 694 708 4.38% DCHLAQVPSHTVVAR 
     431.4575 3 1291.5503 399 409 5.84% WCAVSE(OOH)EATK 
606.30426 2 1210.54 558 567 94.33% DSGFQ(OxM)NQLR 
    1043.561 2 2084.996 146 162 4.32% RLPGV(OHKyW)(OOW)CAVGH(OOH)ERAK 
 
 
 
MS/MS analysis of the oxidatively modified peptide DSGFQ(OxM)NQLR (m/z 606.30426) 
 
shows a significantly high score of 94.33% for OxM with a single O atom (See Fig.16). 
 
However, the analysis of the theoretical peptide modified by His (OOH) (m/z 431.4575) 
 
revealed a non significant low score of 5.84% with 2 O atoms. MS/MS analysis of oxidatively 
 
modified peptide RLPGV(OHKyW)(OOW)CAVGH(OOH)ERAK (m/z 1043.561) revealed a 
 
non significant score of Trp oxidation products, 3-hydroxykynurenine (OHKyW) and OOW. 
 
As shown in Fig.16, OxM showed a strong y-type ion series y1, y2, y4, y6 and y7. However, 
 
one a-type ion is also shown (a2-) which retains the N-terminal residue. The presence of  
 
these ions in the spectrum increases the score of the sequence containing OxM (94.33%)  
 
and enables confident assignment of both the site and the type of modification. The relatively 
 
high signal to noise (S/N), apparent in Fig.16, adds to more confidence in identifying the site 
 
of modification. 
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Fig. 16: Annotated MS/MS spectrum for the peptide DSGFQ(OxM)NQLR 
 
(m/z 606.30426) showing singly charged y-ion series . 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                                                    
 
                                                                              
 
84 
 
6.6.3 Sample P4A  
 
Table 14 shows m/z, charges, score of the minimally modified peptide,  
 
CLVDLN(KyW)NNLEGK of protein digest of plasma  Sample P4A  of a patient with HH  
 
Mass: 1.0068246E7   Score: 5.18%  Coverage: 2.06%  
 
Mz Charge Mr(calc) Start End Score Peptide 
761.42236 2 1520.7292 588 600 26.61% CLVDLN(KyW)NNLEGK 
 
MS/MS analysis of the peptide CLVDLN(KyW)NNLEGK (m/z 761.42236), shows a relatively 
 
low score of 26.61% for KyW (See Fig.17). 
 
Figure 17 shows the annotated MS/MS spectra of m/z 761.42236 from the in vivo sample  
 
P4A. Seven y-type ions are assigned (y2, y4, y5, y7, y8, y9, y12).  
 
 
 
 
Fig. 17: Annotated MS/MS spectrum for the peptide CLVDLN(KyW)NNLEGK m/z 
 
          761.4223 with singly charged y-type ions. b-type ions are not shown.  
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Figure 18 shows the annotated MS/MS of m/z (761.4239) from tissue sample P4A (the same 
 
above sample but different peptide.  
 
Seven y-type ions are shown (y2, y4, y5, y7, y8, y9, y12). y-type ions retain the C- terminal 
 
residues. 
 
 
 
 
 
 
 
Fig. 18: MS/MS spectrum of m/z 761.4239 from tissue sample P4A, annotated by PEAKS 
 
after database matching against transferrin (Accession gi|62897069; 88.2% 
 
confidence). 
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6.6.4 Sample P6 
 
Table 15 shows m/z, charges, score of the minimally modified peptides, 
 
 DECMVKWCAIG(OxH)QER and TSDANIN(KyW)NNLK of  protein digest of plasma Sample  
 
  P6 of a patient with HH. 
 
 
Mass: 77753.2   Score: 7.54%   Coverage: 3.84% 
    
Mz Charge Mr(calc) Start End Score Peptide 
607.53143 3 1819.7803 360 374 37.04% DECMVKWCAIG(OxH)QER 
697.3981 2 1392.6633 457 468 2.16% TSDANIN(KyW)NNLK 
 
 
 
                                         The MS/MS analysis of the peptides DECMVKWCAIG(OxH)QER, m/z (607.5314) and 
 
TSDANIN(KyW)NNLK m/z (697.3981) show a relatively low score of 37% for OxH and 
 
2.16% for KyW respectively. 
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6.6.5 List of in vitro samples that have most fragment ion peaks in  
  
         common with oxidized peptide MS/MS spectra from samples of 
 
         patients with HH 
 
1) Peptide DSGFQ(OxM)NQLR (m/z 606.3042) found in sample P2A (see Fig. 17, page  
 
    106), the best match was the (m/z 606.3192) MS/MS spectrum from the in vitro sample  
 
    002 (see Fig. 7, page 78), which matched transferrin with 73.2% confidence. Peaks were  
  
    observed in both spectra are m/z 175.1 (a2/y1), 288.2 (y2), 530.3 (y4), 805.5 (y6) and  
 
    952.5 (y7). 
 
2) Peptide SASDLT(OxW)DNLK (m/z 633.1517) found in sample P2 (see Fig. 15, page 101),  
 
    the best match was the m/z (633.4001) MS/MS spectrum from the in vitro sample DT4  
 
    {denatured transferrin treated with 20 uM hydrogen peroxide and 2 equivalents of  
 
    FeNAc3}, (Fig.10, page 89), which matched transferrin with 99% confidence. Peaks were  
  
   observed in both spectra are m/z 260.2 (y2), 374.3 (y3) and 633.4 (the doubly-charged  
 
    precursor ion itself).  
 
3) Peptide TAGWNIP(OxM)GLLYNK (m/z 797.5013) also found in sample P2 (see Fig.16,  
 
    page 103), the best match was the m/z (797.5536) MS/MS spectrum from the in vitro  
 
    sample NT4 {native transferrin treated with 20 uM hydrogen peroxide and 2 equivalents of  
  
    FeNAc}, (Fig. 9, page 86), which matched transferrin with 65.3% confidence. Peaks  
 
    observed in both spectra are m/z 261.2 (y2), 424.3 (y3), 887.6 (unassigned), 951.6 (y8)  
 
    and 797.6 (the doubly-charged precursor ion itself). 
 
4) A MS/MS spectrum for an unmodified peptide KLCGDEWSVNSVGK (m/z 761.4224, 2+  
  
    charge) that was detected in a real sample (P4) because it occurred to have a m/z ratio  
 
    close to one of the target modified (oxidized) peptides, CLVDLN(KyW)NNLEGK, found in  
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our in vitro samples, and which matches transferrin with good confidence (88%), confirming 
 
that this protein is present. 
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6.7 Detection of protein carbonyls in plasma samples of patients with HH 
  
As shown in Fig. 19 (B), compared to the controls, samples 2, 3, 4, 5 recorded a significantly 
 
high content of protein carbonyls (1-7 times) which correlated with the relative levels of serum 
 
ferritin and transferrin saturation regardless of whether the patients were homozygous or 
 
heterozygous to C282Y or H63D. Sample 2 recorded the highest carbonyl content among all 
 
(80.3 ± 44.8 pmol/µL). This sample was from a patient with active hepatitis due to HCV  
 
infection, as well as high serum ferritin, 1517 ng/L (normal: 20–250 ng/L) and high serum 
 
transferrin saturation, 93% (normal: 17 – 50%) (Table 3, Page 50). The genotypic testing of  
 
this patient revealed one copy of H63D. The lowest carbonyl content was from a patient with  
 
serum ferritin of 182 ng/L and serum transferrin saturation of 54%. This patient reported a  
 
carbonyl content of 15.0 ± 20.5 pmol/µL. The genotypic testing of this patient revealed two  
 
copies of C282Y (Table 3, Page 50). The average from our controls (n = 6) recorded a  
 
carbonyl content of 10.03 ± 4.2 pmol/µL plotted against the average from patients with HH (n  
 
= 6) which had a carbonyl content of 35.5 ± 23.9 pmol/µL (Fig. 19 A). These findings  
 
compared well with those of Houglum et al. (1997). They tested 15 subjects for each group  
 
of control as well as untreated and treated patients with genetic hemochromatosis.  
 
According to Houglum et al., genetic hemochromatosis patients had increased transferrin  
 
saturation and serum ferritin levels prior to treatment compared to control and treated  
 
patients. Their data and ours showed a significant positive correlation between the level  
 
of carbonyl content and serum ferritin concentration as shown in Fig. 20 which shows a  
 
linear relationship between ferritin content and carbonyl content of plasma samples from  
 
controls and patients with HH. 
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6.7.1 Statistical Analysis 
 
Unpaired t test results:  
    
P value and statistical significance: The two-tailed P value equals 0.0278 (P< 0.05), by  
 
 conventional criteria, this difference is considered to be statistically significant. 
  
Confidence interval: 
 
The mean of Controls minus HH Patients equals -25.4700 
 
95% confidence interval of this difference: From -47.5434 to -3.3966  
 
 Intermediate values used in calculations: 
 
      t = 2.5710 
 
     df = 10 
 
    standard error of difference = 9.907  
 
Group Controls  HH Patients  
Mean 10.0300 35.5000 
    SD 4.2000 23.9000 
SEM 1.7146 9.7571 
    N 6  6  
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
                                                                    
 
                                                                              
 
91 
 
(A) 
 
0.0
33.3
66.7
100.0
Controls HH_Pateints
Groups
P
ro
te
in
 C
ar
bo
ny
l C
on
te
nt
s 
(p
m
ol
/u
L)
 
(B) 
 
         
0.0
25.0
50.0
75.0
100.0
Controls HH_1 HH_2 HH_3 HH_4 HH_5 HH_6
Patient Groups
P
ro
te
in
 C
ar
bo
ny
l C
on
te
nt
s 
(p
m
ol
/u
L)
 
Fig.19 (A) and (B): Carbonyl groups, an index of oxidative stress, are increased in HH  
 
 Patients. (A) Box Plots of Carbonyl groups controls (n = 6; 10.03 ± 4.2 pmol/µL) and  
    
 HH patients (n = 6; 35.5 ± 23.9 pmol/µL). (B) Standard Deviation Bar Graph of  
 
 Controls and Individual HH Patients Samples. 
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 Fig. 20.  Linear relationship between carbonyl content and ferritin in plasma samples from  
 
               patients with HH and controls. 
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7.0 Discussion 
 
The detection of the oxidative modification of proteins has been used as a marker of  
 
oxidative stress. Oxidative stress can occur when ROS production is accelerated or when the 
 
mechanisms involved in maintaining the normal reductive cellular milieu are impaired (either 
 
by depletion of antioxidants or mutations affecting antioxidant defence enzymes such as Cu/ 
 
Zn-SOD). Increased production of ROS is thought to occur more frequently than diminished 
 
antioxidant defence (Dalle-Donne, I. et al. 2003). It should be emphasized that the detection 
 
of more than one marker for oxidative stress is strongly recommended to avoid the  
 
misleading results that might be given by depending on only one marker. In our experiments, 
 
we detected more than one marker to confirm oxidative injury that may lead to disturbance of 
 
iron homeostasis in untreated patients with hereditary hemochromatosis. 
 
We were able to detect oxidative modifications in different amino acid residues such as 
 
tryptophan, methionine and histidine in vitro by inducing oxidative stress and iron overload in  
 
commercial horse spleen ferritin and human serum transferrin (Sigma). The proteins were  
 
subjected to tryptic digestion prior to analysis by Q-TOF LC-MS/MS. The modified peptides 
 
were targeted for possible identification of oxidative modifications in plasma samples of  
 
patients of hereditary hemochromatosis. 
 
7.1 Protein Carbonylation and Lipid Peroxidation as Biomarkers of Oxidative Stress 
        
Protein carbonyl content is the most general and well-used biomarker of severe oxidative  
 
protein damage. Protein carbonyls have a major advantage over the lipid peroxidation 
 
products as markers of oxidative stress because of their stability and their early and 
 
prolonged circulation in the blood. In our experiments, we used the detection of protein  
 
carbonyls as a preliminary and general procedure to indicate if oxidative stress has a role in  
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the pathophysiology of hereditary hemochromatosis. For this purpose, 2, 4-  
 
dinitrophenylhydrazine (DNPH) was used to detect protein carbonyls in the plasma samples  
 
of untreated patients of hereditary hemochromatosis. This technique is based on the reaction 
 
between protein carbonyls and DNPH resulting in the formation of a Schiff base to produce  
 
the corresponding hydrazone, which can be analyzed spectrophotometrically. A significantly 
 
high content of protein carbonyls (1-7 times), compared to the control, were detected. 
 
These findings correlate positively with the relative levels of serum ferritin. One of our  
 
samples recorded a particularly high carbonyl content. This sample was from a patient with 
 
active hepatitis due to HCV infection as well as high serum ferritin, 1517 ng/L (normal : 20 - 
 
250 ng/L) and high serum transferrin saturation, 93% (Normal : 17 - 50%). This finding  
 
supported the suggestions of Koike, K. et al. (2006) that oxidative stress is involved in the 
 
pathogenesis of hepatitis and hepatocellular carcinoma. However, the genotypic testing of  
 
this patient revealed one copy of H63D. Piperno et al. (1992) studied the presence of  
 
antibodies to hepatitis B and C viruses, serum ALT concentrations, hepatic histology, and  
 
total body iron stores (assessed by phlebotomy) in 78 Italian patients with hemochromatosis.  
 
We also reported another patient who recorded a relatively low carbonyl content despite the  
 
fact that he was homozygous for C282Y but serum levels of ferritin and transferrin saturation  
 
were low. There was no significant difference reported between the carbonyl contents of  
 
homozygous or heterozygous individuals for C282Y and H63D which supports the  
 
suggestion of the involvement of oxidative stress in the pathogenesis of hereditary 
  
hemochromatosis due to the oxidative modifications of ferritin and transferrin regardless of  
 
whether the patients were homozygous or heterozygous for the C282Y and H63D mutations  
 
(unpublished observation).The positive correlation between high plasma carbonyl content  
 
and high plasma ferritin suggested that the pool of catalytic iron increases in parallel with the 
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hepatic iron and may be linked to enhanced lipid peroxidation (Houglum, K.et al 1997). This  
 
positive correlation still does not explain any direct links between HFE and ferritin metabolism  
 
but it is possible that the abnormal protein synthesized as a consequence of mutated HFE  
 
gene directly or indirectly leads to disturbances in ferritin metabolism or iron loading. In HH,  
 
elevated plasma ferritin occurs in the absence of architectural damage to the liver,  
 
suggesting that the elevated plasma ferritin results, most likely, from enhanced secretion of  
 
ferritin rather than tissue damage. At this point, the plasma proteins that are oxidatively  
 
modified in untreated patients with HH, as measured by carbonyl assay, have not yet been  
 
characterized since the elevation of carbonyl levels may be due to the oxidation of any other  
 
plasma protein rather than transferrin. We characterized the oxidatively modified plasma  
 
protein (transferrin) by using an antibody to isolate it for tryptic digestion and Q-TOF LC-MS/  
 
MS analysis. 
 
Houglum et al. (1990) have indicated that plasma proteins synthesized by hepatocytes such  
 
as transferrin, are modified by MDA- and 4-HNE-lysine adducts, decomposition products of 
 
lipid peroxidation in a rat model of iron overload. As well, they have detected MDA-lysine  
 
adducts and autofluorescence in hepatocytes of iron-overloaded rats. In support of a 
 
hepatocellular origin for aldehyde-protein adducts is the finding that levels of 4-HNE and 
  
MDA-protein adducts in the blood circulation of animals are stable despite the removal of the 
  
iron from the diet (Houglum et al. 1990). Furthermore, Houglum et al. could not detect the 
 
presence of an aldehyde-transferrin adduct, as transferrin did not correspond with MDA and 
 
4-HNE in the plasma samples of iron-overloaded rats. Shacter et al. (1995) did not suggest 
 
transferrin as a major plasma protein target for oxidative modifications. Free or catalytic iron 
 
increases in the livers of rats overloaded with iron and it is thought that this iron pool, and not 
 
iron sequestered in ferritin or hemosiderin, promotes lipid peroxidation (Britton et al. 1990). 
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Surprisingly, Houglum et al. (1997) could not detect MDA-protein adducts in plasma proteins 
 
of plasma samples of patients of HH using the same Western blot analysis technique used  
 
with plasma samples or iron-overloaded rats. They indicated that the cause for this might be 
 
the insidious rate of iron accumulation in the liver of HH patients which contrasts with the  
 
rapid iron loading in the animal model. 
 
Carbonyl iron (a highly purified form of elemental iron) has been used by Bacon and  
 
colleagues (1983) to evaluate the role of chronic iron overload in promoting lipid peroxidation 
 
in vivo by examining subcellular fractions of liver from chronically iron-loaded rats for the 
 
presence of lipid conjugated dienes, intermediates in the peroxidative degradation of 
 
polyunsaturated lipid membranes. They supplemented the diet of Sprague-Dawley male 
 
rats with 2.5% (wt/wt) carbonyl iron. This feeding regimen predominantly produced iron 
 
loading of hepatocytes in a peripheral distribution, similar to that of hemochromatosis.  
 
Significant quantities of iron were deposited after, as early as, two weeks in rats fed on the 
 
carbonyl-iron diet. Iron continued to accumulate in hepatocytes for three months until stores  
 
of iron in hepatocytes were 40-90 times of those of control animals with the development of  
 
signs of hepatic necrosis. After eight months, Kupffer cells and macrophages were heavily 
 
invaded with iron deposits. Twelve months were quite enough to ensure hepatic fibrosis and  
 
necrosis reproducing an experimental model of the pathophysiology of hemochromatosis. We 
 
suggest that Bacon et al. may have designed a model for hemochromatosis based on the  
 
fact that iron overload leads to hepatic injury due to oxidative stress. This may not be an ideal  
 
model for HH because some other factors, such as the levels of plasma ferritin and  
 
transferrin saturation, should be considered to avoid confusion with any other iron overload  
 
disorder. However, this model has been described before even the discovery of HFE gene in  
 
1996. Many other groups have used this model to demonstrate the hepatotoxic effects of 
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excess iron on peroxidation of organelle membranes, organelle function including lysosomal  
 
fragility, impairment of mitochondrial oxidative metabolism, abnormalities in calcium transport 
 
, reduction in the levels of cytochromes a, b, c and cytochrome C oxidase activity and  
 
disruption of metabolic functions of other subcellular organelles (Britton, et al. 1990;  
 
Houglum,et al. 1990; Fletcher, et al. 1989 and Myers et al. 1991). We have confirmed the  
 
presence of protein carbonyls in real samples (plasma samples of untreated patients with  
 
HH)while considering ferritin and transferrin saturation levels as well. 
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7.2 Why Hydrogen Peroxide? 
 
In our in vitro experiments we have induced oxidative stress in commercial protein standards 
 
(Horse Spleen Ferritin and Human Serum Transferrin) by using hydrogen peroxide, which  
 
has been extensively used as an oxidant. As known, most of the oxidative damage in tissues 
 
require  the participation of catalytically active iron (Rudeck, M. et al. 2000). Free iron can  
 
catalyze the decomposition of hydroperoxides, including hydrogen peroxide, resulting in the 
 
formation of highly reactive substances that promotes lipid peroxidation and other oxidative 
 
damage reactions. An increase of this reactive iron is believed to be a pathophysiological  
 
factor in several diseases that are accompanied by oxidative damage. To prevent this  
 
oxidative damage, a system has evolved to limit the concentration of reactive iron but also to  
 
provide iron for biochemical synthesis. Ferritin, as an intracellular protein, binds iron in a  
 
catalytically inactive form; accordingly, oxidative reactions cannot be promoted by this iron. 
 
Because the main iron pool in most cells is located within the ferritin, it is important to know 
 
under what circumstances, if any, this pool may be a source of iron. Ferritin has been shown 
 
to release iron on contact with activated microglia and neutrophils by a superoxide-  
 
dependent mechanism. 
 
Oxidative damage to ferritin that results in a physiological malfunction e.g., the release of  
 
iron,might be accompanied by damage to the apoferritin molecule. Protein oxidation in 
 
mammalian cells is generally accompanied by the degradation of oxidized protein molecules. 
 
However, hydrogen peroxide-induced protein oxidation enhances the proteolytic susceptibility 
 
of the damaged protein. 
 
In our in vitro experiments, we have detected oxidative damage to ferritin and transferrin 
 
molecules following exposure to two different concentrations of hydrogen peroxide (10 and 
 
20 µM). This oxidative damage leads to the modification of both proteins. This was confirmed 
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by Q-TOF LC-MS/MS which detected a number of oxidatively modified peptide fragments  
 
containing oxidized methionine, histidine, and tryptophan that were identified using PEAKS 
 
software. Mapping of the oxidized Ferritin residues showed that the modified residues were 
 
located on the inner face of each sub-unit, the face directed toward the ferritin core where 
 
inert iron is normally stored. 
 
Our findings partially correlate with those of Rudeck and co-workers who showed that the 
 
treatment of ferritin with hydrogen peroxide increases the oxidative damage and proteolytic 
 
susceptibility of the ferritin molecule dramatically, since iron is released before the maximal 
 
possible degradation of oxidized ferritin has occurred compared to other oxidants such as 
 
xanthine / xanthine oxidase and DEA-NO (Rudeck, et al. 2000). We used EDTA in our first 
 
set of experiments along with hydrogen peroxide as EDTA-Fe (III) complexes to effectively 
 
catalyze ·OH formation, as reported by Aust, S. et al. (1985). The rate of lipid peroxidation 
 
is dependent upon the ratio of chelate (EDTA) to ferric iron. A ratio of less than 1 maximizes 
 
the rate of lipid peroxidation (Aust et al. 1985). A ratio of 1:1 is still able to initiate lipid 
 
peroxidation ; however, a ratio above 1 causes inhibition of lipid peroxidation. The  
 
concentration of EDTA we have used in our experiments was 10 mM, which was chosen to 
 
stop the oxidation reaction at a specific point, prior to the dialysis step, and to enhance the 
 
autoxidation of the proteins. However, we did not detect protein carbonyls in our in vitro 
 
experiments using Q-TOF LC-MS/MS probably because of our low concentration of hydrogen 
 
peroxide (10, 20 µM) or the absence of derivatization with DNPH prior to the oxidation  
 
process (unpublished observation). Headlam, H. et al (2004) have indicated that reaction of  
 
BSA with hydrogen proxide alone over the range of 290-1450 µM gave only low levels of  
 
released carbonyls, and the yield of each of these materials did not increase significantly with  
 
increasing oxidant concentration (lowest yields compared to HOCl, γ radiolysis and other 
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oxidants). However, the addition of Fe (II) (± EDTA) at a fixed concentration to hydrogen 
 
peroxide (290 µM) gave a significant increase in the levels of all released carbonyls. In 
 
contrast, increasing concentrations of Fe (II)-EDTA (in the absence of hydrogen peroxide) 
 
gave significant dose-dependent increases in the yields of released carbonyl compounds  
 
(Headlam, H. 2004). 
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7.3 Autoxidation and Iron Incorporation in Ferritin Molecules 
 
The goal of the first part of our second set of in vitro experiments was to incorporate iron  
 
within horse spleen ferritin by using ferrous ammonium sulfate with ferritin along with two 
 
different concentrations of hydrogen peroxide (10, 20 µM) without the involvement of an iron 
 
chelator (EDTA). The incorporation of iron into the ferritin core using ferrous ammonium  
 
sulfate was dependent on the buffers used, with HEPES and Tris being the most effective, as 
 
well as pH of the buffers. As indicated by Silva, D et al. (1992) at pH 7.0, the initial rate of iron 
 
incorporation was about 0.1 µM/min. When the assay was repeated at pH 6.0, the rate of  
 
incorporation dropped to about 0.01µM/min. At neutral pH, Fe (II) is susceptible to hydrolysis  
 
and autoxidation due to the deprotonation of iron-bound water molecules. As the pH  
 
decreased, the stability of Fe (II) increased. 
 
The presence or absence of iron chelator is also an important factor that might affect iron  
 
incorporation within the ferritin core. However, the presence of a strong iron chelator such as  
 
EDTA or Diethylenetriaminepentaacetic Acid (DPTA) will stabilize Fe (II) preventing or  
 
lessening the iron incorporation into the ferritin core which will lead to slowing the rate of  
 
autoxidation due to iron overload. 
 
We induced oxidative stress using hydrogen peroxide in 50 mM HEPES buffer, pH 7.0  
 
without the involvement of EDTA in these preparations. Silva, et al. (1992) have reported that  
 
incubation of iron-ferritin complex with EDTA for 4 hours was sufficient to remove up to 30%  
 
of the iron from ferritin loaded with ferrous ammonium sulfate. HEPES buffer, which is a poor  
 
chelator of iron, allows the greatest oxidation of ferrous iron since it does not compete well,  
 
either with protein for metal binding or with water for coordination to free sites on the metal. 
 
However, the incorporation appeared to be related to the rate of autoxidation (De Silva et  
 
al. 1992), i.e. the more iron incorporation, the highest rate of autoxidation obtained. The rapid 
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autoxidation of Fe (II) can give rise to the production of superoxide, hydrogen peroxide, and 
 
the hydroxyl radical via the iron-catalyzed Haber-Weiss reaction. These species are capable  
 
of altering biological molecules such as ferritin via modification of amino acid residues  
 
(Stadtmen, E. et al. 1991), and may result in the loss of integrity of the protein. It is known  
 
that the oxidation of proteins results in preferential proteolysis in vivo. The availability of iron  
 
and hydrogen peroxide is fundamental to these metal-catalyzed oxidation processes. The  
 
production of hydroxyl radical during the non-enzymatic deposition of iron into ferritin has  
 
already been demonstrated, and it was proposed that this was confined to the interior of the  
 
molecule (data not published) which undoubtedly causes localized damage to the protein. 
 
On the other hand, according to De Silva et al. (1992), the loading of apoferritin by  
 
ceruplasmin was not dependent on the autoxidation of iron, and amino acid analysis revealed 
 
no damage to the protein shell during iron incorporation in this system. This would account  
 
for the lack of amino acid oxidation observed during ceruplasmin-dependent loading of 
 
ferritin. Welch, K. et al. (2001) could not determine the effect of loading of iron into ferritin via  
 
ceruplasmin on the modification of tryptophan which was not the case in our experiments  
 
using ferrous ammonium sulfate as an iron source for incorporation within ferritin core.  
 
Welch et al. have demonstrated that loading iron into ferritin altered the 3-D conformation 
 
or tertiary structure of the protein such that new sites were accessible to trypsin. Many of the 
 
new recognition sites were close to cysteine residues. This suggests that the cysteine  
 
residues were oxidized and consequently the tertiary structure of the protein in the vicinity 
 
of the cysteine residues was altered. Many studies have shown that oxidation does alter the 
 
tertiary structure of the protein. 
 
7.3.1 Ferritin oxidation and ·OH production  
 
According to Grady, J. et al. 1989, ·OH produced from the iron-catalyzed Haber-Weiss 
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reaction is a by-product of core formation in ferritin. As described above, radical production 
 
appears to be confined to the interior of the ferritin molecule, where cellular components  
 
would be protected from the oxygen-mediated oxidative damage to the protein, a process 
 
that may contribute to the formation of hemosiderin from ferritin. 
 
Hemosiderin is thought to be formed from the aggregation and the partial degradation of the 
 
ferritin protein shell by lysosomal enzymes. Hemosiderin peptides are derived from ferritin 
 
peptides and free radical catalyzed reactions are likely involved in the transformation. 
 
Hemosiderin is known to have smaller iron cores, and its protein shell is less complete than 
 
that of ferritin. While both proteins release iron and promote lipid peroxidation and hydroxyl  
 
radical formation, hemosiderin is consistently and significantly less effective than ferritin  
 
(Grady et al. 1989). It seems that transformation of ferritin into hemosiderin is a part of free  
 
radical mediated oxidation of the protein. Grady et al. have indicated that hydroxyl radicals 
 
were observed indirectly by using the spin-trapping reagent N-tert-butyl-α-phenylnitrone 
 
(PBN) at room temperature and directly by measuring ESR spectra of frozen molecules at 77  
 
K, at which a PBN-R adduct is observed with both ferritin and apoferritin and not in the  
 
absence of protein. This suggests that the trapped species is derived from the protein itself 
 
and not simply from the iron core (Grady et al. 1989). However, diminution of the ESR signal 
 
by the use of known hydroxyl radical scavengers and enhancement of the signal by the 
  
addition of hydrogen proxide strongly suggested the involvement of hydroxyl radical in the 
 
formation of PBN-R adducts. 
 
To summarise, the hydroxyl radicals are thought to be formed during iron mobilization from  
 
ferritin core by a strong chelator such as EDTA with the involvement of an oxidant such as 
 
hydrogen peroxide or via iron incorporation into ferritin core by ferrous ammonium sulfate or  
 
ceruplasmin. 
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7.4 Autoxidation and Iron Incorporation in Transferrin Molecules 
 
Iron uptake by transferrin has been analyzed by a relatively small number of investigators. 
 
The goal of the second part of our second set of in vitro experiments was to incorporate iron 
 
within human serum transferrin by using ferric nitrilotriacetate along with two different  
 
concentrations of hydrogen peroxide (10, 20 µM) without the involvement of an iron chelator 
 
(EDTA). Twenty mM of sodium bicarbonate was added to transferrin to extract iron very  
 
rapidly from ferric nitrilotriacetate to yield an iron-loaded C-site complex which deprotonates  
 
and undergoes a fast change in conformation, followed by loss of two or three protons which 
 
is, in turn, followed by other slow changes of conformation leading to iron uptake by the N- 
 
site (Chahine, E. et al. 1996). The reaction of ferric salts with transferrin has been  
 
extensively studied by Bates, G. et al. (1973). They have reported that adding iron salts to  
 
buffered transferrin solutions in the neutral to alkaline pH range gives poor results. This was  
 
correlated with our preparations by adding nitrilotriacetic acid to ferric chloride at pH 2, raised  
 
gradually to 6, which provides a rapid and stable chelate-free ferric transferrin.  
 
Bates, G. et al. (1973) have reported that titration of transferrin with ferric nitrilotriacetate  
 
gives a linear function and clear end point, while titration with ferric chloride results in a  
 
sigmoidal-shaped curve and no clear end point is reached. According to them, the spectral  
 
data indicate that only 5 to 25% of the iron becomes bound when 1 eq of ferric chloride is  
 
added to transferrin at neutral pH. The remaining sites of the protein are vacant and available  
 
for reaction with ferric nitrilotriacetate. In our methods, we have allowed one and two  
 
equivalents of ferric nitrilotriacetate to react with transferrin to bind the C-site iron load and  
 
total (C+N)-site iron load, respectively. As expected, we have detected much more modified 
 
methionine, tryptophan and histidine peptides when we used 2 equivalent of ferric  
 
nitrilotriacetate due to the occupation of C- and N–sites with iron rather than occupying only 
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the C-site using one equivalent of ferric nitrilotriacetate. As a consequence, iron uptake by 
 
transferrin leads to protein damage, which was detected oxidative modifications of  
 
methionine, histidine and tryptophan. However, no significant difference has been detected  
 
between the samples treated with low and high concentrations of hydrogen peroxide. The 
 
decomposition of hydrogen peroxide by ferric ions occurs but it is considerably slower than  
 
the Fenton’s reaction.  
 
Like the Fenton’s reaction, it appears to be a redox chain reaction: 
 
       Fe (III) + H2O2         Fe (II) + HO2· + H 
 
This reaction, as indicated above, has an acidic pH optimum. At neutral pH, the reaction is 
 
extremely slow due to the tendency of ferric ions to hydrolyze. The reduction of ferric ions is 
 
critical as transferrin molecules have a weak affinity for ferrous ions that would facilitate its 
 
release, leading to transferrin autoxidation (Aust et al. 1985). It is speculated that at low pH, 
 
decreased stability of the Fe(III)-transferrin complex and the involvement of anions such as 
 
phosphate and bicarbonate are crucial for transferrin autoxidation. Iron incorporation has  
 
been reported in vivo by Bacon et al. (1983) after a single intraperitoneal injection of rats with 
 
ferric nitrilotriacetate (Fe-NTA) which gives rise to evenly distributed iron deposits over the 
 
hepatic lobules compared with the heavy iron deposits in hepatocytes due to dietary carbonyl 
 
iron. This is due, in part, to saturation of transferrin with subsequent increased endocytosis in  
 
a scenario which resembles a model for hereditary hemochromatosis. The low concentration  
 
of transferrin often found in the disease also appears to reflect the increased iron stores, and 
 
the concentration returns to normal after iron-depletion therapy. It seems unlikely that 
 
hemochromatosis is related to a primary defect in transferrin (Cartei, G. et al. 1975). 
 
Cartei et al. proposed a defect in the transferrin molecule but they did not define this defect. 
 
We suggest a possible defect in the transferrin molecule due to hereditary hemochromatosis. 
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This suggested defect is due to oxidative modification of transferrin yielding modified  
 
peptides of methionine, tryptophan and (data not published). Cartei et al. (1975) have  
 
demonstrated that venesection therapy causes the rise of plasma transferrin due to the  
 
removal of iron overload and not to venesection per se. Another possible defect in  
 
hemochromatosis is the decreased ability of reticuloendothelial cells to retain iron. The result  
 
of this defect is a return of greater amounts of iron from stores to plasma ferritin, increasing  
 
its iron saturation and thus causing more iron saturation and directing more iron into  
 
hepatocyte storage. 
 
Furthermore, iron absorbed through the intestinal mucosal cells in the face of almost  
 
complete saturation of transferrin is taken up selectively by the hepatic parenchymal cells. 
 
Batey, R. et al. (1980) have confirmed the existence of a non-transferrin-bound iron (NTBI) 
 
fraction in the sera of patients with untreated or inadequately treated primary  
 
hemochromatosis. The high NTBI concentration in primary and secondary hemochromatosis, 
 
and in normal serum with an artificially elevated serum iron, suggest that the NTBI is a result 
 
of transferrin being fully saturated, thus preventing additional iron binding by serum  
 
transferrin, although this may not be the only explanation for the findings in primary  
 
hemochromatosis (Batey, et al. 1980).  
 
Batey, et al. also have reported on four patients who, at diagnosis of primary 
 
hemochromatosis, had normal serum iron concentration and transferrin saturation and a  
 
raised NTBI level. This correlates with our record of having two untreated patients with  
 
normal plasma iron and transferrin saturation, although their genotypic tests confirmed  
 
C282Y and H63D mutations and having the clinical indicators of primary hemochromatosis.  
 
Batey’s records and ours suggest that iron binding to transferrin may be altered because of  
 
some additional factor. 
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We suggest that this factor might be a defect in transferrin molecule that hinders the binding  
 
capacity of the transferrin receptor, and which is closely related to the oxidative transferrin  
 
modification confirmed by detection of protein carbonyls and modified methionine and  
 
tryptophan residues in plasma samples from these patients (data not published). Aruoma, O.  
 
et al. (1988) have confirmed the presence of low molecular weight iron in plasma from  
 
hemochromatosis patients, even when their plasma transferrin is far from saturation. A  
 
possible interpretation of this data is that, in hemochromatosis, iron enters the plasma from  
 
the gut in a NTBI form that is rapidly cleared by the liver and does not bind quickly to any  
 
transferrin available. Thus, the concentration of Bleomycin-detectable iron (NTBI) in plasma  
 
at anytime would presumably reflect a balance between entry of iron from the gut and its  
 
clearance by the liver (Aruoma, et al. 1988). Lehotay, D. et al (2001) have related the  
 
elevated NTBI only to hemochromatosis patients, and not other patients with elevated iron  
 
status parameters. We have tested plasma of patients severely affected patients with HH for  
 
congenital defects of glycosylation (CDG) syndrome by evaluation of immunoreactive forms  
 
of transferrin after IEF (Isoelectric Focussing) in polyacrylamide gels. The test revealed the  
 
absence of N-glycosylation defects associated with sialic acid deficiency. As is already 
 
known, carbohydrate–deficient Trf (CDT) plays an important role as a marker of chronic  
 
abuse and of congenital disorders of glycosylation such as COPD and cystic fibrosis. Hence,  
 
the defect we are suggesting in the transferrin molecule due to HH seems more likely to  
 
result from oxidative modification than N-glycosylation disorders. 
 
7.4.1 Does transferrin–bound iron affect lipid peroxidation? 
 
Cutteridge, J. et al. (1981) have saturated both lactoferrin and transferrin with iron to  
 
investigate the effect of partially iron-loaded transferrin on lipid peroxidation. They suggested 
 
that lactoferrin and transferrin, at physiological degrees of iron saturation, are inhibitors of 
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iron-dependent lipid peroxidation. This is due to their iron-binding capacities, since saturation  
 
of the proteins with iron abolished their inhibitory effect and indeed, might have caused them 
 
to have a pro-oxidant effect.  
 
Cutteridge, et al. (1985) have differentiated between transferrin-bound iron and NTBI. As 
 
indicated above, they suggested that transferrin-bound iron inhibits lipid peroxidation. Most 
 
recently, they indicated that sera from patients with idiopathic hemochromatosis often contain 
 
iron detectable by the bleomycin method. They also suggested that a total serum iron greater  
 
than 40 µM is associated with the presence of bleomycin-detectable iron. According to  
 
Cutteridge et al. (1985), in at least one patient, the bleomycin-detectable iron was capable  
 
of stimulating both the peroxidation of lipids and the formation of the highly destructive  
 
hydroxyl radical. The transferrin in this patient’s serum was essentially fully iron-saturated. In  
 
normal sera or partially iron-loaded transferrin sera, no iron can be detected by the bleomycin  
 
method. This observation might explain why we detected transferrin modification in samples 
 
of plasma from certain patients with HH while it was not detectable in other patients with the 
 
same disease. As indicated in Table 3, it seems that the patients with iron > 40 µM were  
 
prone to develop oxidative injury due to the full saturation of transferrin with iron. Hence, the 
 
iron found in the sera or plasma of iron-overloaded patients with idiopathic hemochromatosis 
 
is capable of stimulating oxygen radical reactions, which could contribute to the pathology of  
 
the disease. 
 
7.4.2 Is Iron-loaded Transferrin able to generate ·OH? 
 
As known, transferrin is the iron-transport protein of the human plasma. In the presence of a 
 
suitable anion (carbonate) it binds 2 molecules of Fe (III)/mol of protein. There is a dispute in  
 
the literature concerning the ability of transferrin-bound iron to accelerate ·OH formation and  
 
lipid peroxidation. McCord and Day (1978) reported that iron-loaded transferrin promoted ·OH 
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formation from superoxide and hydrogen peroxide at pH 7.4. This observation has been  
 
supported by others. Baldwin et al (1984) have indicated that iron-loaded transferrin was not  
 
active in accelerating ·OH formation at pH 7.8. Halliwell et al. (1985) have reported that ferric  
 
ions might become released from transferrin at low pH values (e.g. in ischemic tissues or in  
 
the microenvironment of activated phagocytic cells) in a form able to promote radical  
 
reactions, since iron can be mobilized from the protein under acidic conditions. 
 
We suggest that transferrin-bound iron in vitro and in vivo is not active in accelerating  
 
oxidative damage at physiological pH unless a strong chelating agent is present. We have 
 
attempted to address this possibility in our first set of in vitro oxidation experiments with  
 
ferritin and transferrin by using hydrogen peroxide and EDTA as a chelating agent in  
 
physiological PBS at pH 7.4. The outcome was a damage of both proteins leading to their  
 
autoxidation, with several peptides containing oxidized methionine, tryptophan and histidine 
 
being detected. Furthermore, in our second set of in vitro oxidation experiments with  
 
transferrin, in the absence of EDTA, we achieved even greater damage of the transferrin  
 
molecule in the presence of carbonate and ferric nitrilotriacetate at an acidic pH which  
 
promoted the radical reactions. It seems that pH as well as chelating agents are playing an  
 
important role in initiating oxidative injury.  
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7.5 Methionine Oxidation  
 
7.5.1 Significance of In Vitro Met Oxidation 
 
Methionine is one of the most readily oxidized amino acid residues of proteins. It is  
 
attacked by hydrogen peroxide, hydroxyl radical, hypochlorite and peroxynitrite. Under the 
 
effect of methionine sulfoxide reductase, methionine sulfoxide (the initial methionine oxidation  
 
product) can be reduced back to methionine. However, a higher concentration of hydrogen  
 
peroxide or any other oxidant will lead directly to the production of the irreversible oxidation  
 
product, methionine sulfone, without intermediate generation of hydroxyl radicals (Vogt, W.   
 
1995). Functional changes by Met oxidation in a given protein appear to have  
 
pathophysiological significance in some diseases such as rheumatoid arthritis, emphysema  
 
and, recently, hereditary hemochromatosis in which Met is converted into Met sulfoxide.  
 
Considering the reversibility of Met oxidation in some instances, it seems possible that Met 
 
oxidation/reduction in proteins may be involved in maintaining homeostasis in biological  
 
systems. Met sulfoxide can be formed as a Met oxidation product in vivo but formation of 
 
sulfone (irreversible oxidation product) is unlikely, although this is possible via in vitro  
 
experiments since we can control the strength of the oxidizing agent. 
 
Based on these considerations, the development of a disease due to Met oxidation is most  
 
likely due to accumulation of Met oxidation products and/or the involvement of another  
 
oxidation marker rather than dependence upon the production of irreversible oxidation  
 
product (sulfone) in vivo, which as we have described, is unlikely. 
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Fig.21: oxidation products of Methionine  
 
 
Oxidation of up to 10% of the C-terminal methionine residues in proteins can occur  
 
spontaneously. The best-known methionine-selective chemical oxidants are chloramines T 
 
(Cl-T) and N-chloro-succinimide (N-Cl-S). Cl-T is a relatively mild oxidant that, at pH 7.0 or 
 
higher, oxidizes only cysteine and methionine residues, whereas N-Cl-S also attacks 
 
tryptophan. An extremely specific oxidant for methionine residues is dimethyl sulfoxide.  
 
Under proper conditions it leaves even cysteine intact (Vogt, 1995). 
 
Methionine can be oxidized by biologically relevant oxidants such as superoxide, hydrogen 
 
peroxide, hydroxyl radical and hypochlorous acid which are products of PMN  
 
(polymorphonuclear neutrophils) leukocytes and other phagocytic cells used to damage  
 
invading organisms in defence reactions of the host (Vogt, 1995). In our methods, we have 
 
used one of these biologically relevant oxidants (hydrogen peroxide) to achieve a better  
 
matching for in vivo future findings. With the exception of superoxide, all such oxidants can  
 
oxidize methionine to the sulfoxide. Furthermore, methionine was extensively oxidized, 
 
yielding the highest scoring modified peptides for ferritin and transferrin in both in vivo  
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and in vitro work. We suggest that, provided catalytic amounts of iron are present, rather low  
 
concentrations of hydrogen peroxide are sufficient to oxidize methionine. In the first portion of  
 
our in vitro work, we obtained an abundance of modified methionine residues in the presence  
 
of EDTA (iron chelator), which is known to enhance protein autoxidation. 
 
In the second portion of our in vitro work, we obtained even higher scores for oxidatively  
 
modified methionine residues in the absence of EDTA. This underscores the role of transition 
 
metals (iron or copper) as catalysts for the decomposition of the hydrogen peroxide-  
 
producing hydroxyl radical in the course of tissue damage or oxidative stress. 
 
7.5.1.1 Inhibition of Met Oxidation 
 
For In vitro studies, scavengers of oxidants are used for either of two purposes: (1) to stop  
 
the reaction of the oxidants with proteins (specifically with methionine); or (2) in the case of  
 
complex biological systems, to obtain some indications on the nature of the active oxidant  
 
leading to the effect observed by Vogt (1995). The first case is most applicable to our  
 
experiments since, specificity is not required; any agent that reacts with the oxidant but does  
 
not interfere with the product or its estimation can do the work. Ethanol, mannitol, and  
 
dimethyl sulfoxide have all been used as scavengers for hydroxyl radicals. Iron chelators,  
 
such as EDTA, can be used for abrogation of further production of hydroxyl radicals (reported  
 
in our Materials and Methods Section). 
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7.5.2 Is there a relationship between methionine and tryptophan oxidation? 
 
The detection of both Met and Trp oxidation in both our in vitro and in vivo experiments  
 
requires more detailed discussion. 
 
Taylor, S et al. (2003) assumed Trp oxidation to be analogous to Met oxidation, known to 
 
be an artifact of sample handling, since there is no correlation between Trp oxidation and  
 
the Met oxidation, thereby suggesting they occur via different mechanisms. In other words, 
 
the method of preparation is not a factor in determining the extent of oxidation or the  
 
presence of oxidation in one sample and its absence in another sample. 
 
Taylor et al. reported that Met oxidation appears to be related directly to the number of 
 
observable peptides, as would be expected if oxidation were a random sample-handling  
 
artifact. In contrast, Trp oxidation appeared much more specific to selected subunits. 
 
In our in vitro experiments we have detected Met and Trp as well as His oxidative  
 
modifications. Met is the most susceptible amino acid for oxidation by several oxidants such 
 
as hydrogen peroxide, our oxidizing agent of choice. Furthermore, the severity of oxidation  
 
varied between iron release and iron incorporation models since, we detected more oxidized  
 
Met residues among those samples with iron incorporation compared to those with iron  
 
release. Of course, random sample-handling artifact will never differentiate between both  
 
preparations. Furthermore, the absence of gel separation in our protocol reduces the risk of  
 
random Met oxidation. Taylor’s observations that Met and Trp oxidations are not correlated  
 
further strengthens our hypothesis that the observed Met oxidation is real . Our in vivo  
 
findings indicated the presence of oxidized Met peptides in plasma samples from certain  
 
patients with HH. These and Trp oxidations detected in other samples support our contention  
 
that Met oxidation is not artifacted. 
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7.6 Tryptophan Oxidative Modification as a Biomarker of Oxidative Stress 
 
Metal-catalyzed oxidation (MCO) is a primary oxidizing system in many cell types. The 
 
oxidative effects of MCO (Fenton reaction) on the structure of tryptophan residues was 
 
extensively investigated. Finely, E. et al (1998) have investigated the structure of the  
 
tryptophan and methionine residues of bovine α-crystallinin eye lenses. Oxidation of proteins 
 
via the Fenton reaction depends on the ability of the protein to bind iron; that is, proteins with 
 
high affinity for iron are readily oxidized (Samuni et al. 1990; Stadtman, 1992). The presence  
 
of an EDTA-Fe complex prevents oxidation of proteins that binds iron (Stadtman, 1990,  
 
1992). 
 
The oxidation of tryptophan to N-formylkynurenine in proteins is well established. Taylor et al. 
 
(2003) have suggested that tryptophan residues are “hot spots“ for oxidation in respiring 
 
mitochondria. The most interesting aspect of tryptophan oxidation is its irreversibility as  
 
reported by Spector, A. et al. (1995) as he indicated its occurrence in cataractogenesis  
 
causing severe and irreversible opacity of the eye lenses. Finley, E. et al. 1998 have  
 
confirmed these findings. As we have mentioned above, tryptophan and methionine  
 
oxidations are not related. They might confirm the occurrence of oxidative stress. In our in  
 
vivo experiments, the occurrence of both oxidations gives support and strength to our  
 
hypothesis regarding the involvement of oxidative stress in altering the homeostasis of iron  
 
metabolism due to hereditary hemochromatosis that might be one of the cornerstones of the  
 
pathophysiology of this disease. 
 
On page 97, we have detected a score of 7.83 % for OxW  which was apparently low.  
 
However, this oxidative modification was repeated in different samples which might give  
 
more support for the effect of tryptophan oxidation in The pathology of HH. 
 
Tryptophan oxidation has never been detected as an artefact or as a reversible condition. On 
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the other hand, methionine oxidation has been detected as an artifact, a reversible or an 
 
irreversible condition. 
 
So, to indicate whatever a pathological condition is due to methionine oxidation we have to 
 
meet at least one of these 2 criteria: first, further investigations that will lead to the  
 
information that the oxidation we have is irreversible. 
 
Second, using other markers for oxidative stress to confirm oxidative damage. In our 
 
experiments, we had 2 more markers, both were irreversible (protein carbonyls and Trp 
 
oxidation). However, Trp oxidation has been reported as an indication of cataractogenesis, 
 
 whether the score of peptides containing oxidized tryptophan residues was high or not,  
 
 simply because it has never been detected as a reversible condition or as an artefact, as  
 
 mentioned above. 
 
 If in our in vivo experiments, we ONLY detected Met oxidation, that would never 
 
 support the notion of having oxidative stress unless this data was supported with other data 
 
 (as carbonyls or Trp oxidation). We suggest that Trp oxidation is most likely to be 
 
supportive. I think we cannot apply the conditions of the in vitro experiments TYPICALLY 
 
 to the in vivo environment. However, the reason we have conducted the in vitro experiments 
 
 prior to the in vivo ones was to target such modified peptides as a guide to identify the same  
 
 in real (biological) samples rather than concerning about scores. 
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8.0 Conclusions   
 
1. Ferritin and transferrin can be oxidatively modified in vitro by iron  
 
      immobilization via an iron chelator (EDTA) OR iron incorporation. 
 
2. Mapping of the oxidatively modified ferritin residues were shown to be 
 
      situated on the inner face of each subunits (the face directed toward the 
 
      ferritin core. 
 
3. Hereditary Hemochromatosis is an ideal model for iron overload. 
 
4. Fully Iron-saturated transferrin is a source of oxidative stress via low-  
 
      molecular-weight iron and non-transferrin bound iron. 
 
5. Methionine and tryptophan oxidations are confined to those plasma samples 
 
      of HH patients who showed high transferrin saturation values and carbonyl  
 
      content. 
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